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Gαq signaling is implicated in a number of physiological processes that include 
platelet activation, cardiovascular development and smooth muscle function. Historically, 
Gαq is known to function by activating its effector, phospholipase Cβ. Desensitization of 
Gαq signaling is mediated by G-protein coupled receptor kinases (GRK) such as GRK2 
that phosphorylates the activated receptor and also sequesters activated Gαq and Gβγ 
subunits. Our crystal structure of Gαq-GRK2-Gβγ complex shows that Gαq forms 
effector-like interactions with the regulator of G-protein signaling (RGS) homology 
domain of GRK2 involving the classic effector-binding site of Gα subunits, raising the 
question if GRK2 can itself be a Gαq effector and initiate its own signaling cascade. In 
the structure, Gα and Gβγ subunits are completely dissociated from one another and the 
orientation of activated Gαq with respect to the predicted cell membrane is drastically 
different from its position in the inactive Gαβγ heterotrimer. 
 vii 
Recent studies have identified a novel Gαq effector, p63RhoGEF that activates 
RhoA. Our crystal structure of the Gαq-p63RhoGEF-RhoA complex reveals that Gαq 
interacts with both the Dbl homology (DH) and pleckstrin homology (PH) domains of 
p63RhoGEF with its C-terminal helix and its effector-binding site, respectively. The 
structure predicts that Gαq relieves auto-inhibition of the catalytic DH domain by the PH 
domain. We show that Gαq activates p63RhoGEF-related family members, Trio and 
Kalirin, revealing several conduits by which RhoA is activated in response to Gq-coupled 
receptors.  
The Gαq effector-site interaction with p63RhoGEF/GRK2 does not overlap with 
the Gαq-binding site of RGS2/RGS4 that function as GTPase activating proteins (GAPs). 
This suggests that activated G proteins, effectors, RGS proteins, and activated receptors 
can form high-order complexes at the cell membrane. We confirmed the formation of 
RGS-Gαq-effector complexes and our results suggest that signaling pathways initiated by 
GRK2 and p63RhoGEF are regulated by RGS proteins via both allosteric and GAP 
mechanisms. 
Our structural studies of Gαq signaling provide insight into protein-protein 
interactions that induce profound physiological changes. Understanding such protein 
interfaces is a key step towards structure-based drug design that can be targeted to treat 
diseases concerned with impaired Gαq signaling.  
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Chapter 1 
 
Introduction  
 
 
 
 
 
 
 2 
Introduction to G protein-coupled Receptor Signaling 
 
Signal transduction that relays extracellular signals to changes in intracellular function is 
a fundamental cellular process. One such signal transduction pathway is that of 
G protein-coupled receptors (GPCRs), which are involved in a wide range of 
physiological functions, such as the release of neurotransmitters and hormones, 
maintaining transmembrane ion flux, activation or repression of gene transcription, and 
whole cell decisions such as cell proliferation, survival or death. Moreover, GPCRs are 
the target for more than 30% of the prescribed pharmaceutical drugs on the market 
(Schoneberg, Schulz et al. 2004; Lagerstrom and Schioth 2008).   
 
GPCRs are transmembrane proteins that are encoded by a large family of over 800 genes 
in the human genome and are present in yeast, plants, protozoa and metazoa. They are 
primarily classified into at least five subfamilies based on sequence homology: rhodopsin 
(family A), secretin (family B), glutamate (family C), adhesion (family D) and 
frizzled-taste-2 (family E) and the rhodopsin family of receptors including ~90% of all 
GPCRs (Schoneberg, Schulz et al. 2004). Although GPCRs bind to diverse kinds of 
ligands such as amines, peptides, amino acids, glycoproteins, phospholipids, fatty acids, 
Ca2+ ions, odorants, tastants, pheromones, and light, all GPCRs share a common 
molecular architecture comprised of seven transmembrane α-helices, an extracellular N-
terminus, an intracellular C-terminus and three interhelical loops on either sides of the 
membrane. The C-terminal tail contains an eighth α-helix and palmitoylation sites 
 3 
(Kristiansen 2004; Schoneberg, Schulz et al. 2004{Kristiansen, 2004 #15; Oldham and 
Hamm 2008).  
 
 
Figure 1.1: Model of signaling through GPCRs. Ligand or hormone activated receptor 
(GPCR) catalyzes nucleotide exchange of GTP for GDP on the Gα subunit. Gα·GTP and 
Gβγ can then induce intracellular signaling by activating their respective effector 
molecules. Gα subunits have an intrinsic GTPase activity that in some cases can be 
accelerated by regulator of G protein signaling (RGS) proteins. The resulting Gα·GDP 
reassociates with Gβγ, completing the G protein cycle.  
 
GPCRs activate heterotrimeric GTP binding proteins (G proteins) that consist of 
GTP/GDP binding Gα subunit, Gβ and Gγ subunits (Gαβγ) (Fig 1.1). Upon activation, 
GPCRs act as guanine-nucleotide exchange factors (GEFs) to promote GDP dissociation, 
 4 
and GTP binding to Gα subunit. Both Gα·GTP and Gβγ subunits then relay signal by 
binding to their respective effector molecules and thereby bring on rapid changes in the 
concentration of intracellular second messengers such as adenosine 3,5-monophosphate 
(cAMP), diacylglycerol (DAG), inositol phosphates and ions. All Gα subunits have an 
intrinsic GTPase activity, which results in subsequent re-association of Gα·GDP and Gβγ 
subunits into the inactive Gαβγ heterotrimer. GTPase activating proteins (GAPs) such as 
regulator of G protein signaling (RGS) proteins and in some cases effectors, themselves 
can enhance the intrinsic GTPase activity of some Gα subunits, thereby accelerating the 
termination of G protein cycle (Fig 1.1). 
 
Termination of GPCR signaling commonly occurs by a process of homologous 
desensitization in two steps. The agonist-activated receptors are first phosphorylated by 
G protein-coupled receptor kinases (GRKs). These phosphorylated receptors are then 
bound by a family of proteins called arrestins that can block heterotrimeric G proteins 
from coupling with the GPCRs. Arrestins also targets the receptor for clathrin-mediated 
endocytosis (Hepler and Gilman 1992; Krupnick and Benovic 1998; Pierce, Premont et 
al. 2002; Cabrera-Vera, Vanhauwe et al. 2003).  
 
Heterotrimeric G-protein Structure 
 
In humans, there are 21 Gα (coded by 15 genes), six Gβ (coded by 5 genes) and 12 Gγ 
subunits. Gα proteins are divided into four subfamilies based on the sequence similarity 
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of the Gα subunits: Gαs, Gαi/o, Gαq and Gα12/13, each of which stimulate specific 
downstream effectors. Activated Gαs or Gαi/o either activate or inhibit adenylyl 
cyclase (AC) resulting in the increase or decrease in cAMP levels, respectively. Activated 
Gαq activates phospholipase C β (PLCβ) leading to formation of inositol triphosphate 
(IP3) and diacyclglycerol (DAG). Activated Gα12/13 mainly stimulates certain Rho 
guanine nucleotide exchange factors (RhoGEFs) that further stimulate the activation of 
small GTPases like RhoA. Dissociated Gβγ subunits also signal to a number of effectors 
such as PLCβs, ACs, phosphotidylinositide 3-kinase (PI3K), K+ and Ca2+ channels 
(Sprang 1997; Sprang, Chen et al. 2007).  
 
Gα subunits are peripheral membrane proteins that are anchored to the membrane by 
lipid modification. All Gα subunits except Gαt are palmitoylated at positions in the 
N-terminus. Members of the Gαi subfamily are also myristoylated at the N-terminus.  
The Gα subunits are typically 39-52 kDa in size and consist of two conserved sub-
domains, a GTPase/Ras-like domain and a α-helical domain (Fig. 1.2 & 1.3). The 
GTPase domain is composed of a six-stranded β-sheet surrounded by five α-helices and 
the helical domain comprised of six α-helices. Highly conserved consensus sequences are 
found in five loops used for guanine nucleotide binding: the diphosphate-binding (P) loop 
or Walker A motif (GXGESGKS), the Mg2+ binding loops (RXXTXGI and DXXG) and 
the guanine ring binding motifs (NKXD and TCAT). There are also three flexible loops 
in the GTPase domain near the γ-phosphate binding site termed switches I, II and III that 
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are conformationally sensitive to the state of the bound nucleotide (GDP or GTP) 
(Oldham and Hamm 2006); (Sprang, Chen et al. 2007).  
 
 
Figure 1.2: Crystal Structure of Gα i1.·GTPγS·Mg2+. The secondary structures of the 
α-helical domain are labeled with letters (e.g. αA) and that of GTPase domain are labeled 
with numbers (e.g. α1 and β2). N and C refer to the amino and carboxyl termini of the 
protein. Mg2+ is shown in black as a sphere. GTPγS, a slowly hydrolyzing analog of GTP 
is depicted as ball and stick model. The three switch regions that undergo a 
conformational change upon nucleotide exchange (GDP Vs GTP) are colored red. 
(PDB ID: 1GIA) 
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Figure 1.3: Sequence alignment of Gα  subunits. The switch regions are highlighted in 
red. The secondary structures (assigned based on structure of Gαi1 PDB ID: 1GG2) are 
depicted as cylinders for α-helices and arrows for β-strands. The labeling of secondary 
structures is as shown in Fig. 1.2. The sequences are those of rat Gαi1 GI: 121020, bovine 
Gαt GI: 121031, bovine Gαs GI: 121000, mouse Gαq GI: 84662745 and mouse Gα13 
GI: 120984.   
 8 
 
The switch I region contains the Mg2+ binding loop and together with P loop participates 
in the GTPase reaction. The switch II region contributes to the binding pocket for the γ-
phosphate binding, and becomes less ordered upon GTP hydrolysis. Switch III region is a 
loop-helix segment that contacts switch II through ionic interactions. These switch 
regions also form a substantial part of the interface formed with Gβγ subunits, 
downstream effectors and regulatory proteins (Fig. 1.5, 1.6, 1.7, 1.8). The amino and 
carboxyl termini of Gα subunits are expected to play an important role in receptor 
binding specificity and G protein activation (Sprang, Chen et al. 2007). 
 
Gβ subunits are ~36 kDa and have a seven-bladed β propeller structure containing seven 
WD40 repeats (Fig 1.4): Each blade is composed of four anti-parallel β strands. One 
WD40 repeat contributes to the last three strands of one blade and the first strand of the 
neighboring blade. The N-terminus of Gβ adopts an α-helical conformation. The Gβ 
subunit engages the switch I and switch II loops of Gα subunit in its GDP bound state 
and also forms extensive interactions with the N-terminal helix of the Gα subunit. 
 
The Gγ subunit is a small protein of ~8 kDa. It is lipid modified in its C-terminus by 
farnesylation or gerenylgerenylation. It is comprised of two α-helices (Fig. 1.4). The N-
terminal helix interacts with the N-terminus of Gβ in a coiled-coil structure. The C-
terminal helix contacts blades 5 and 6 of Gβ subunit. The Gβ and Gγ subunits form one 
stable functional unit that can be separated only by denaturation. There are no observed 
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contacts in the crystal structures between Gα and Gγ subunits. (Wall, Coleman et al. 
1995; Bohm, Gaudet et al. 1997; Sprang 1997; Sprang 1997; Cabrera-Vera, Vanhauwe et 
al. 2003). 
 
Figure 1.4: Structure of G protein Gβ1γ2. Gβ1,shown in blue, has an N-terminal helix 
followed by seven β sheets forming a β propeller structure. The seven β sheets are 
labeled numerically. Gγ2, shown in green, formed a coiled coil with the N-terminal helix 
of Gβ. (PDB ID: 1GP2) 
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Receptor-mediated G protein Activation 
 
The crystal structures of visual GPCR rhodopsin, β1-adrenergic receptor (β1-AR), 
β2-AR and squid rhodopsin have been determined (Palczewski, Kumasaka et al. 2000; 
Salom, Lodowski et al. 2006; Cherezov, Rosenbaum et al. 2007; Rasmussen, Choi et al. 
2007; Rosenbaum, Cherezov et al. 2007; Murakami and Kouyama 2008; Warne, Serrano-
Vega et al. 2008). The overall structures of GPCRs are similar, with seven 
transmembrane helices and an eighth helix running parallel to the cytoplasmic face 
of the membrane. Two models have been proposed for the initial encounter of activated 
receptor with G-proteins. The ‘collision coupling model’ suggests that G-proteins interact 
with activated receptors by free-lateral diffusion with the plasma membrane, while the 
‘precoupling model’ suggests that G-proteins can bind receptors before agonist binding 
(Oldham and Hamm 2006; Oldham and Hamm 2008{Oldham, 2006 #25). Fluorescence 
and bioluminescence resonance energy transfer experiments provided conflicting results 
for precoupling of α2A-adrenergic receptor and Gαi1β1γ2 (Hein, Frank et al. 2005; Gales, 
Van Durm et al. 2006). Studies in the rhodopsin signaling support the precoupling model 
of G protein activation. Although the light activated rhodopsin binds Gt with an apparent 
Kd of ~1 nM and catalyzes nucleotide exchange of GDP for GTPγS on transducin, it was 
shown that the inactive dark rhodopsin can also couple to transducin (Gt) with an 
apparent Kd of 64 nM, suggesting that inactive GPCR likely precouples to G proteins 
(Alves, Salgado et al. 2005). 
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Agonist binding induces a conformational change in the cytoplasmic domains of the 
receptor resulting in ‘active’ receptor that not only activate G proteins but also interact 
with GRKs and arrestins. Site-directed spin labeling experiments in rhodopsin have 
shown that activation of receptor basically results in an outward movement of helix VI 
and cross-linking helix III and VI by artificial disulfides disrupted receptor stimulated 
activation of G-protein transducin (Farrens, Altenbach et al. 1996; Sheikh, Zvyaga et al. 
1996). A similar mechanism is proposed for other receptors such as the β2-adrenergic 
receptor, the thyrotropin-releasing hormone receptor and M3-muscarinic receptor (Jensen, 
Guarnieri et al. 2001; Huang, Osman et al. 2005; Ward, Hamdan et al. 2006). The 
movement of helix VI is hypothesized to open a cleft on the cytoplasmic side of the 
receptor, that serves as the binding site for the C-terminus of Gα, the best characterized 
receptor interacting interface on Gα (Janz and Farrens 2004). Residues in the α4-β6 loop 
and the N-terminal helix of Gα and the C-termini of Gβ and Gγ subunits have also been 
implicated in binding to the receptor. The receptor interaction site of Gα (C-terminus and 
α4-β6 loop) is ~30 Å away from the nucleotide binding pocket. Hence, the receptor is 
thought to induce a conformation change in G protein that causes the release of GDP and 
further binding to GTP (Oldham and Hamm 2006; Oldham and Hamm 2008). Structural 
and kinetic elements that link agonist binding to conformation changes in receptor 
followed by receptor mediated nucleotide exchange on Gα is an active area of research. 
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Figure 1.5: Model of receptor-G protein coupling. The crystal structure of rhodopsin 
(PDB ID: 1GZM) is juxtaposed next to the structure of Gt heterotrimer (PDB ID: 1GOT). 
Rhodopsin is colored in pink, Gαi/t is colored in cyan with sand-colored β strands, Gβ1 is 
shown in blue and Gγ1 is in green. The switch regions are colored red. GDP bound to Gα 
is shown as ball and stick model. Retinal bound to rhodopsin is colored yellow. 
Biochemical studies suggest that the intracellular loops of the receptor contact the N-
terminus, C-terminus and the α4-β6 loop of Gα subunit. The C-terminus of Gβ and Gγ 
are also implicated in receptor binding (Oldham and Hamm 2006).  
 
 
 13 
G-protein Inactivation 
 
The Gα subunit has an intrinsic GTPase activity that can be modulated by bound 
effectors (Sprang 1997). Gα subunits of the Gi, Gs and Gq family have a slow single 
turnover GTP hydrolysis rate of 2-5 min-1 (Gilman 1987). The crystal structures of Gα in 
a series of structural states along the progression of the catalysis of GTP hydrolysis have 
been determined. These include the structures of Gα⋅GTPγS⋅Mg2+, Gα⋅GDP⋅AlF4- (a 
mimic of the putative pentavalent transition state), Gα⋅GDP⋅Pi and Gα⋅GDP (Coleman, 
Berghuis et al. 1994; Mixon, Lee et al. 1995; Wall, Coleman et al. 1995; Berghuis, Lee et 
al. 1996; Raw, Coleman et al. 1997; Coleman and Sprang 1998; Coleman and Sprang 
1999).  Kinetic and structural studies indicate that two amino acid residues, Arg178 and 
Gln204 (in Gαi1), play a direct role in the catalysis of GTP hydrolysis (Fig. 1.6). Both 
residues bind and stabilize the putative pentavalent transition state, while the glutamine 
residue also orients the attacking nucleophilic water molecule. Ser47 in the P-loop and 
Thr181 in switch I loop are involved in contacting the Mg2+ion.  
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Figure 1.6: Reaction intermediates in the Gα il 
catalyzed hydrolysis of GTP. (A) Gαi1 in active 
state, mimicked by a complex with GTPγS·Mg2+ 
(PDB ID: 1GIA). (B) The transition state of GTP 
hydrolysis is represented as Gαi1in complex with 
GDP·AlF4-·Mg2+ (PDB ID: 1GFI). R178 and Q204 
reorient to likely stabilize the negative charge of 
pentavalent γ phosphate and orient the attacking 
nucleophilic water molecule, respectively. 
(C) Gαi1in complex with GDP·Pi (PDB ID: 1GIT) 
(D) Gαi1in complex with GDP (PDB ID: 1GG2). 
These structures point at the conformational 
changes that occur during the course of GTP 
hydrolysis and signal termination.  
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GTPase Activating Proteins 
 
Physiological responses initiated by Gα such as phototransduction have been observed to 
terminate faster than the intrinsic GTPase rate. For example, the half time for hydrolysis 
of GTP bound to isolated Gαt is 15 s, but vision responses terminate with in 100 ms. The 
rate of GTP hydrolysis by Gα subunits of the Gi and Gq subfamily can be accelerated to 
over several thousand fold by GAPs. Gα GAPs include the GAP domains of effector 
proteins and a family of RGS proteins (Ross and Wilkie 2000).  
 
PLCβ is a classic example of a Gα effector that can also function as a GAP. PLCβ can 
stimulate the steady state GTP hydrolysis rate of Gαq to over 1000 fold when 
reconstituted in lipid vesicles with M1-muscarinic acetylcholine receptor 
(Mukhopadhyay and Ross 1999). Deletion mapping studies show that interaction of Gαq    
with the C-terminus of PLCβ1 is required for both the stimulatory activity of Gαq and for 
the GAP activity of PLCβ1 (Sprang, Chen et al. 2007). The molecular mechanism of how 
PLCβ functions as a GAP is not known. 
 
To date, there have been over 30 mammalian RGS proteins identified, which can be 
classified into at least six subfamilies based on the sequence homology (Hollinger and 
Hepler 2002; Bansal, Druey et al. 2007). These include A/RZ, B/R4, C/R7, D/R12, E/RA 
and F/RL. All RGS proteins have a conserved ~120 amino acid RGS domain, that 
mediates GAP activity to different extents by directly binding to Gαi or Gαq.  All RGS 
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GAPs bind preferentially to the GDP·Mg2+·AlF4- bound form of Gα and have very low 
binding affinity for the GDP and GTPγS bound forms (Sprang, Chen et al. 2007) 
(Berman, Kozasa et al. 1996). Hence RGS proteins are thought to function as GAPs by 
stabilizing the GTPase transition state conformation.  
 
Our current understanding of the molecular details of Gα interaction with RGS proteins 
comes from the crystal structures of Gαi1·GDP·AlF4--RGS4 complex (Tesmer, Berman et 
al. 1997), PDEγ-Gαt/i1·GDP·AlF4--RGS9 complex (Slep, Kercher et al. 2001), 
Gαo·GDP·AlF4-·RGS16 complex (Slep, Kercher et al. 2008) and structures of RGS 
proteins of R4, R7, R12, and RZ subfamilies (Soundararajan, Willard et al. 2008). The 
RGS domain comprises of nine α-helices that fold into two subdomains called the 
terminal (α1, α2, α3, α8 and α9) and the bundle (α4, α5, α6 and α7) subdomain. The 
α3-α4 loop, the α5-α6 loop and residues at the end of α7 and the beginning of α8 helix 
are involved in binding Gα, contacting all three switch regions of Gα (Fig. 1.7).  In 
particular, Asn128 in the α3-α4 loop of RGS4 orients the catalytic Gln204 of Gαi1, 
constraining it to interact with the lytic water molecule and the γ phosphate of GTP.  
Although the structural differences in Gα-RGS interfaces of Gαi1-RGS4 structure, PDEγ-
Gαt/i1-RGS9 structure and Gαo·GDP·AlF4-·RGS16 complex are subtle; several RGS 
proteins exhibit differential selectivity towards the various Gα targets. For example, 
RGS4 can accelerate the rate of GTP hydrolysis on Gαi and Gαq, but RGS2 is shown to 
be selective for Gαq (Heximer, Cristillo et al. 1997) (Ingi, Krumins et al. 1998). 
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Figure 1.7: (A) Structure of Gα i1·GDP·AlF4- in complex with RGS4. Gαi1 is depicted 
in cyan with sand-colored β-strands. The switch regions are colored red. RGS4 (shown in 
green) interacts with all three switch regions of Gαi1 to stabilize the transition state of 
GTP hydrolysis. (B) A close up view of Gαi1·GDP·AlF4- -RGS4 interface. RGS4 residues 
are shown in green and Gα residues are shown in cyan. Asn128 of RGS4 traps the 
catalytic Gln204 of Gα to interact with lytic water molecule. Side chain rotation of 
Thr182 in switch I enables the formation of a network of hydrogen bonds between Asn88 
and Glu87 of RGS4 and Glu207 and Lys210 in switch II of Gαi1. Hydrogen bonds are 
depicted by grey lines (PDB ID: 1AGR). 
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G protein-Effector Complexes 
 
Gα subunits in their GTP bound state bind effectors with high affinity. The members of 
each of the four subclasses of Gα subunits are related in sequence and in most cases bind 
the same set of effectors in their active GTP bound state. Our current insight into the 
structural details of Gα-effector complex comes from the crystal structures of Gαs bound 
to the catalytic domain of AC (Tesmer, Sunahara et al. 1997), Gαt bound to PDEγ in the 
presence of RGS9 (Slep, Kercher et al. 2001); Gα13 bound to p115RhoGEF (Chen, 
Singer et al. 2005) and our structures of Gαq bound to GRK2 (Tesmer, Kawano et al. 
2005) and Gαq bound to p63RhoGEF (Lutz, Shankaranarayanan et al. 2007).  
 
Gαs, or the stimulatory Gα subunit, is the classic activator of all nine isoforms of AC 
(Gilman 1987; Sunahara, Tesmer et al. 1997). Golf, activated by the olfactory receptors, is 
related to Gs and also activates AC. AC is the effector enzyme that converts adenosine 
triphosphate (ATP) to cAMP, a second messenger molecule that stimulates several 
cellular responses by activating cAMP-dependent protein kinases. The catalytic core of 
the enzyme is formed by two cyclase homology domains (CHDs), C1 and C2, which are 
preceded by putative multiple-pass membrane spanning domains in the intact enzyme. 
The C2 domains can readily form homodimers, but the formation of C1C2 heterodimer is 
essential for catalytic activity. The major interface between Gαs and the C1C2 heterodimer 
is formed by the switch II  (α2) helix of Gαs and the α2 helix in the periphery of the C2 
domain. A second contact involves the very N-terminus of C1 domain forming a 
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hydrophobic contact with the α3 helix of Gαs (Fig. 1.8). Binding of Gαs to these 
peripheral sites of C1 and C2 domains allosterically promotes the formation of an active 
catalytic interface between C1 and C2 domains (Tesmer, Sunahara et al. 1997).  
 
The Gαi (inhibitory) subfamily includes all isoforms of Gαi, Gαt, Gαo and Gαz. The 
isoforms of Gαi inhibit AC activity. Biochemical and mutagenesis studies suggest that 
Gαi1 is thought to form a Gαi1-C1 complex that assumes a conformation that does not 
allow stable formation of catalytically active Gαi1-C1-C2. (Dessauer, Chen-Goodspeed et 
al. 2002; Sprang, Chen et al. 2007).  
 
Gαt, or transducin, is activated by rhodopsin in visual rod cells Gα and activates cyclic 
guanosine monophosphate (cGMP) phosphodiesterase (PDE). In order to improve protein 
expression for structural studies, several chimeric versions of transducin and Gαi1 have 
been used (Skiba, Bae et al. 1996); since then several Gα chimeras have been used for 
structural and biochemical studies. Structural studies from the Sigler lab have shown the 
molecular details of Gαt interaction with the inhibitory γ subunit of PDE in the presence 
of the GTPase activating protein, RGS9 (Slep, Kercher et al. 2001). The chimeric Gαt 
used in the study, Δ25Gαt/i1, had residues (216-294) replaced with the corresponding 
homologous region of Gαi1 (220-298), which includes the switch III region, α3 helix and 
the α3-β5 loop. Similar to Gαs interaction with AC, Gαt/i1 contacts PDEγ with residues 
from switch II (α2) helix, α3 helix and the α3-β5 loop (Fig. 1.8). By sequestering the 
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inhibitory γ subunit, Gαt relieves PDEαβ subunits to perform catalysis of second 
messenger cGMP to produce GMP.  
 
Gα12/13 activates a subclass of RhoGEFs called the RH-RhoGEFs; they contain a RGS 
homology domain (RH) positioned N-terminal to a tandem Dbl homology (DH)/ 
pleckstrin homology (PH) domains. RH-RhoGEFs includes three members namely 
p115RhoGEF, PDZ-RhoGEF and leukemia associated RhoGEF (LARG). The DH/PH 
domain represents the functional unit of all RhoGEFs that catalyze the nucleotide 
exchange of GDP for GTP on small G-proteins such as RhoA, Cdc42 and Rac1 
(Rossman, Der et al. 2005). The GEF activity of RH-RhoGEFs is believed to be 
autoinhibited by oligomerization mediated by segments in their C-terminal region 
(Sprang, Chen et al. 2007). The crystal structure of Gα13/i (a chimera of Gα13 and Gαi) in 
complex with p115RhoGEF (1-249 residues) has been solved (Fig. 1.8). The RGS-like 
domain (43-249) binds to Gα like AC or PDEγ, in that it interacts with a narrow canyon 
between the switch II- α3 helix. (Chen, Singer et al. 2005).  
 
Thus, all three Gα-effector complex structures show a common effector recognition 
surface on Gα that comprise of the (switch II) α2 helix together with α3 helix and the 
α3-β5 loop of the Gα protein (Fig. 1.8). Our crystal structure of the 
Gαq-p63RhoGEF-RhoA complex (Chapter 3) also shows that p63RhoGEF recognizes the 
same effector recognition surface on Gαq. It is intriguing how nature has mandated 
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structurally and functionally diverse effectors to recognize a common interaction surface 
on Gα subunit. 
 
Figure 1.8: Gα-Effector complexes. All Gα subunits are colored cyan with sand-
colored β-strands. The switch regions are colored red. (A) Gαs·GTPγS in complex with 
VC1 and IIC2 (colored pink and purple, respectively) domains of AC bound to forskolin 
and a non-hydrolysable analog of ATP (PDB ID: 1CJT). (B) Gαt/i·GDP·AlF4- in complex 
with PDEγ (purple) and RGS9 (green) (PDB ID: 1FQJ). (C) Gαi/13·GDP·AlF4- in complex 
with p115RhoGEF (PDB ID: 1SHZ). The N-terminal GAP domain of p115RhoGEF is 
colored green and the RGS-like domain is colored purple. Note in all Gα-Effector 
structures, the effector recognition surface involves α2 helix, α3 helix and α3-β5 loop in 
Gα. 
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Termination of GPCR Signaling 
 
Although signaling by Gα is turned off upon GTP hydrolysis, it can soon be activated 
again by the activated GPCR. A major mechanism for termination of signaling at the 
GPCR-level is by activation-dependent desensitization called homologous 
desensitization. Activated receptor is phosphorylated by a family of G protein-coupled 
receptor kinases (GRKs), which leads to subsequent binding of arrestin molecules that 
target receptor for endocytosis. Other mechanisms involve receptor activation-
independent desensitization or heterologous desensitization. One example is the 
phosphorylation of receptor by second-messenger related kinases such as cAMP-
dependent protein kinase and protein kinase C. Receptor phosphorylation by these 
kinases alone is sufficient to impair its ability to signal to G proteins (Krupnick and 
Benovic 1998; Pitcher, Freedman et al. 1998; Gainetdinov, Premont et al. 2004).  
 
GRKs are serine/threonine kinases that specifically phosphorylate agonist-occupied or 
activated GPCRs in the carboxyl termini or the third intracellular loop of the receptor. 
There are seven members of GRK family in humans, GRK1 through GRK7. They are 
divided into three subclasses: GRK1-like, GRK2-like and GRK4-like. All GRKs share a 
RGS Homology (RH) domain-kinase domain core and differ in their C-terminal 
membrane-targeting domain (Fig. 1.9). The RH domain is homologous to the classic 
RGS domain found in RGS proteins and the kinase domain is related to the protein kinase 
 25 
A, protein kinase G and protein kinase C (AGC) kinase family (Lodowski, Pitcher et al. 
2003; Lodowski, Tesmer et al. 2006; Singh, Wang et al. 2008).   
 
 
 
Figure 1.9: Membrane-proximal view of GRK2 in complex with G protein Gβγ . The 
PH domain of GRK2 interacts with Gβγ to enable membrane recruitment of GRK2. The 
RH domain, colored purple, forms extensive contacts with the kinase domain and is 
implicated in sequestering Gαq subunit. The kinase domain of GRK2 is colored yellow 
with smudge-colored β-strands. The PH domain is tan-colored, Gβ is colored blue and Gγ 
is depicted in green (PDB ID: 1OMW). 
 
GRK1-like subfamily includes GRK1 (rhodopsin kinase) and GRK7; these are primarily 
found in the retina and regulate the light receptors, the opsins. They are lipid modified by 
farnesylation at their C-terminus. The GRK2-like subfamily includes GRK2 and GRK3. 
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They are ubiquitously expressed and share a carboxyl-terminal pleckstrin homology (PH) 
domain that mediates phosphotidyl inositol bisphosphate (PIP2) and G protein βγ-
mediated translocation of these kinases to the plasma membrane (Fig 1.9). GRK4, GRK5, 
and GRK6 of the GRK4-like subfamily directly bind PIP2 or are lipid modified with 
palmitate at their C-terminus. While GRK5 and GRK6 are widely expressed, GRK4 is 
expressed only in testis (Premont and Gainetdinov 2007). 
 
There are four arrestin genes in humans. While, visual and cone arrestin are exclusively 
expressed in retina, β-arrestin-1 and β-arrestin-2 are widely expressed. Arrestin 
molecules specifically bind ligand occupied and GRK-phosphorylated receptor with high 
affinity and sterically inhibit the coupling of receptor to G proteins (Pierce, Premont et al. 
2002). Further, β-arrestins serve as adapters for β(2) adaptin (AP2) and clathrin  and 
target activated receptors to clathrin-coated pits for endocytosis, and thereby play a 
critical role in receptor recycling and degradation (DeWire, Ahn et al. 2007). Recent 
studies have shown that arrestins can also serve as scaffold for proteins such as Src and 
MAP kinases and initiate a G-protein independent signal cascade (Lefkowitz and Whalen 
2004; Shenoy and Lefkowitz 2005; DeWire, Ahn et al. 2007). 
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Gαq signaling and its physiological roles 
 
Activation of Gq-coupled receptors result in the activation of the β-isoforms of 
phospholipase C that catalyzes the hydrolysis of PIP2 into second messengers, 
diacylglycerol (DAG) and inositol-3-phosphate (IP3) (Fig. 1.10). IP3 binds to receptors on 
the endoplasmic reticulum and signals the opening of Ca2+ channels to increase the 
release of intracellular Ca2+ ions. DAG stimulates the activation of enzymes such as 
Protein Kinase C (PKC). PLCβ can be stimulated by its direct interaction with activated 
Gαq or Gβγ (Hubbard and Hepler 2006; Drin and Scarlata 2007). Recent studies 
demonstrate that activation of Gq-coupled receptors can also stimulate the activation of 
small G protein, RhoA, by direct binding of Gαq with a novel guanine nucleotide 
exchange factor called p63RhoGEF (Fig. 1.10) (Lutz, Freichel-Blomquist et al. 2005).  
 
Gαq has also been reported to bind several other downstream partners such as scaffolding 
proteins (e.g. Caveolin-1, EBP-50, tetratricopeptide repeat 1 (TPR 1), non-receptor 
cytoplasmic activators (Ric 8A, tubulin), non-receptor tyrosine kinase (Btk) and the 
catalytic p110 α subunit of phosphotidyl inositol-3- kinase (PI3K).  Although signaling 
pathways downstream of these interactions are not completely known, it is clear that Gαq 
signaling is functionally diverse and complicated.   
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Figure 1.10: Model of Gαq signaling. Activation of Gαq can lead to activation of 
effectors such as phospholipase Cβ and p63RhoGEF.  Desensitization of Gq-coupled 
receptors involves the phosphorylation of receptor and sequestering of activated Gαq and 
Gβγ by GRK2. 
 
The Gαq subfamily comprises of four members, namely Gαq, Gα11, Gα14 and Gα15/16. 
Genetic investigations have confirmed that double homozygous null mutations of Gαq 
and Gα11 induce embryonic lethality in engineered mice due to cardiac hypoplasia. Mice 
that have one intact allele of the two genes die after birth due to poor cardiac 
development (Offermanns, Zhao et al. 1998). Gαq-coupled receptors in the heart, like the 
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angiotensin II/ endothelin and the α1-adrenergic receptor are key players in normal 
cardiac development and pressure overload cardiac hypertrophy (Dorn and Hahn 2004). 
Gαq knockout mice are also reported to have impaired platelet formation and hence 
increased bleeding times (Offermanns, Mancino et al. 1997; Offermanns, Toombs et al. 
1997). Gq-coupled cholinergic muscarinic receptors in lungs are reported to aid in airway 
smooth muscle function (Borchers, Biechele et al. 2003). The Gq/11 subunits are also 
critical for several neuronal cerebeller activities such as memory, appetite, motor 
coordination and sleep. Mice deficient in Gα14 and Gα15 exhibit normal growth 
characteristics, but have signaling deficiencies (Hubbard and Hepler 2006).   
 
Gαq and Gα11 subunits have a 90% amino acid sequence identity and are expressed 
ubiquitously across tissues. Gα14 and Gα15/16 share a sequence identity of 80% and 57% 
to Gαq, respectively.  Gα14 subunit expression is limited to organs such as kidney, liver, 
lung and bone marrow. Gα15/16 is exclusively expressed at high levels in hematopoietic 
cells prior to differentiation (Hubbard and Hepler 2006). The amino-terminal helix of 
Gαq subfamily is particularly diverse. While Gαq and Gα11 have a 83% sequence identity 
in N-terminal helices, Gα14 and Gα16 have only 65% and 35% identity, respectively, with 
Gαq.  As in other Gα subunits, the amino terminus contains highly charged residues 
contributes to membrane interaction. Biochemical studies have shown that both Gαq and 
Gα11 are lipid modified at their N-terminus by palmitoylation at two cysteines (C9 and 
C10) (Parenti, Vigano et al. 1993). Palmitoylation is critical for its membrane attachment 
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and trafficking and modulation of protein interaction and enzyme activity (Smotrys and 
Linder 2004). 
 
Regulation and Termination of Gαq signaling  
 
The rate of GTP hydrolysis by Gαq can be accelerated by many RGS proteins, but mostly 
by members of the B/R4 subfamily (RGS1, RGS2, RGS3, RGS4, RGS5, RGS8, RGS13, 
RGS16, RGS18) (Heximer, Watson et al. 1997; Ross and Wilkie 2000; Bansal, Druey et 
al. 2007).  These are relatively simple RGS proteins that consist of a N-terminal 
membrane-targeting region followed by the catalytic RGS domain. Apart from 
functioning as GAPs, RGS proteins such as RGS2 and RGS4 can also serve as effector 
antagonists because they inhibit PLCβ signaling stimulated by Gαq bound to a GTPγS 
(Hepler, Berman et al. 1997); (Heximer, Watson et al. 1997). While most of these B/R4 
family members regulate both Gαi and Gαq signaling in cells, RGS2 appears to 
selectively target Gαq both in vitro and in vivo (Hubbard and Hepler 2006).  
 
GRK2 is a robust inhibitor of Gαq-mediated signaling through PLCβ. Not only does the 
kinase domain of GRK2 phosphorylate the activated Gαq-coupled receptor, but also, the 
RH and the PH domain of GRK2 bind activated Gαq/11/14 and Gβγ respectively, thereby 
sequestering the G proteins from activating PLCβ. This latter process is referred as 
phosphorylation-independent desensitization. Thus GRK2 engages all its modular 
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domains to terminate Gαq signaling (Carman, Parent et al. 1999); (Pao and Benovic 
2002); (Sterne-Marr, Tesmer et al. 2003).  
 
Thesis Outline 
 
Given the importance of Gαq signaling in physiological processes, we were interested in 
performing crystallographic and functional studies of Gαq with its effectors and 
regulators. We have developed an expression and purification strategy for Gαq that has 
enabled us to produce sufficient quantities of pure protein to perform structural studies of 
Gαq in macromolecular signaling complexes.  In Chapter 2, we describe the crystal 
structure of Gαq-GRK2-Gβγ complex, explaining the molecular basis of GRK2-mediated 
phosphorylation-independent desensitization of Gq-coupled receptors. The structure 
shows that the RH domain of GRK2 interacts with the classic effector-binding site of 
Gαq raising the question of whether GRK2, like PLCβ or p63RhoGEF, is in fact a third 
downstream effector of Gαq.  
 
We have performed extensive biochemical characterization of Gαq effector, p63RhoGEF 
and also determined the crystal structure of Gαq-p63RhoGEF-RhoA complex that 
provides insight into the mechanism of Gαq mediated stimulation of p63RhoGEF and 
RhoA (Lutz, Shankaranarayanan et al. 2007). The structure shows that Gαq binds to both 
the DH and PH domains of p63RhoGEF with its C-terminus and effector-binding site, 
respectively. The structure suggests that Gαq activates p63RhoGEF by relieving the 
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autoinhibition of the catalytic DH domain by the PH domain. In Chapter 3, we have 
detailed our structural and functional studies of Gαq-mediated activation of RhoA 
through interaction with p63RhoGEF and its related family members, Trio and Duet.  
 
Our structures of Gαq-GRK2-Gβγ complex (Tesmer, Kawano et al. 2005) and 
Gαq-p63RhoGEF-RhoA complex (Lutz, Shankaranarayanan et al. 2007) show that Gαq 
adopts a specific orientation with respect to the predicted membrane plane, such that the 
GRK2/p63RhoGEF interaction site of Gαq does not overlap with the RGS4-like GAP 
binding site of Gαq. The structures predict the formation of high order macromolecular 
complexes of GPCRs, activated G proteins, effectors and regulators at the cell membrane.  
In Chapter 4, we discuss the results of our protein binding assays and functional assays, 
which confirm the formation of RGS-Gαq-GRK2/p63RhoGEF ternary complex. The 
results suggest that Gαq signaling mediated by GRK2 and p63RhoGEF can be regulated 
by RGS proteins through not only its GAP activity, but also through allosteric-dependent 
mechanisms.  
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Chapter 2 
 
Structural Insights into Gαq 
Interactions with GRK2 
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BACKGROUND AND RESEARCH PLAN 
 
G protein-coupled receptor kinases (GRKs) phosphorylate specific serine/threonine 
residues in the third intracellular loop and/or the carboxyl termini of GPCRs to initiate a 
process called homologous desensitization of receptors. In addition to the kinase domain, 
GRKs have additional domains that can modulate their function. The crystal structure of 
GRK2 confirmed that GRK2 (and GRK3) have three domains, the N-terminal RGS 
homology (RH) domain, a central kinase domain and a C-terminal Gβγ binding pleckstrin 
homology (PH) domain (Fig 2.1) (Lodowski, Pitcher et al. 2003; Lodowski, Barnhill et 
al. 2005). Membrane localization of GRK2/GRK3 is mediated by association of its PH 
domain with both Gβγ and anionic phospholipids such as phosphatidylserine and 
phosphatidylinositides (Pitcher, Touhara et al. 1995).  
 
Figure 2.1: GRK2 primary structure and a model of its functional role. Domain 
architecture of GRK2 (top) and cartoon representation of GRK2 mediated desensitization 
of Gαq signaling by interacting with GPCR, Gαq and Gβγ  (bottom). 
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Although cells over expressing GRKs mediate rapid phosphorylation and desensitization 
of receptors, it was observed that GRK2 is capable of promoting phosphorylation 
independent desensitization in Gαq-coupled receptors such as angiotensin II (Oppermann, 
Freedman et al. 1996), the endothelin A and B receptors (Freedman, Ament et al. 1997), the 
thromboxane A2 receptor (TXA2R) (Carman, Parent et al. 1999), the parathyroid hormone 
receptor (Carman, Parent et al. 1999), and metabotropic glutamate receptor 1 (mGluR1) 
(Dhami, Anborgh et al. 2002). It is reported that Gαq in its activated state could bind the 
N-terminal RH domain of GRK2 (Carman, Parent et al. 1999) (Usui, Nishiyama et al. 
2000). Over expression of the N-terminal RH domain alone is sufficient to attenuate 
signaling in the absence of receptor phosphorylation (Carman, Parent et al. 1999; Sallese, 
Mariggio et al. 2000). Also, the kinase deficient mutant of GRK2, K220R is capable of 
inhibiting signaling by Gq-coupled receptors such as mGluR1 (Dhami, Anborgh et al. 
2002). Thus the ability of GRK2 to sequester activated Gαq subunits with its RH domain 
plays a major role in phosphorylation-independent desensitization.  
 
The RH domain of GRK2 binds to activated forms of Gαq, Gα11 and Gα14, and not Gα16 
(Day, Carman et al. 2003). Other Gα proteins (Gαs, Gαi, Gα12/13) do not bind GRK2 
(Carman, Parent et al. 1999; Sallese, Mariggio et al. 2000). The molecular basis of this 
specificity is not clear. Unlike canonical RGS proteins such as RGS4 that preferentially 
bind the GDP·AlF4- bound form of Gαq, the RH domain of GRK2 can also bind GTPγS 
bound Gαq. Also, GRK2 RH domain does not stimulate GTP hydrolysis on Gαq to any 
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significant levels in single turn over GTPase assays. Consistent with GRK2 binding both 
GTPγS and GDP·AlF4- bound form of Gαq, GRK2 serves as an effector antagonist and 
inhibits PLCβ stimulated inositol lipid signaling both in vitro and in intact cells (Carman, 
Parent et al. 1999); (Pao and Benovic 2002).  
 
In order to gain molecular insight into GRK2-mediated phosphorylation-independent 
desensitization, we have determined the crystal structure of Gαq-GRK2-Gβγ complex. 
Although our initial attempts of Gαq purification from E. coli failed, we were able to 
purify a chimeric version of Gαq (Gαi/q) from insect cells that binds GRK2 in an 
activation dependent manner.  Both Gαi/q-GRK2 complex and Gαi/q-GRK2-Gβγ complex 
were subject to crystallization trials. We have crystallized and solved the structure of 
Gαi/q-GRK2-Gβγ complex, which represents the first structure of a Gαq subunit. The 
structure provides a snapshot of activated heterotrimeric G proteins at the membrane 
plane and also describes the Gαq-GRK2 interactions at the molecular level with several 
interesting implications for Gαq signaling.  
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MATERIALS & METHODS 
 
 Attempts of Gαq purification from E. coli 
 
Mouse Gαq (1-359) and a construct lacking the N-terminal 35 residues (Gαq ΔN) were 
cloned into the pMALC2H10T vector using the BamHI and HindIII restriction sites and 
expressed as maltose binding protein (MBP) tagged proteins in Rosetta (DE3) pLyS cells 
(Kristelly, Gao et al. 2004).  The transformed cells were grown in Luria-Bertani (LB) 
media to A600 of 0.8 and protein expression was induced by addition of 100 µM isopropyl 
β-D-1-thiogalactopyranoside (IPTG). The cells were harvested after 20 hrs and frozen as 
pellets in liquid N2. The cell pellet was resuspended in lysis buffer containing 20 mM 
HEPES pH 8.0, 100 mM NaCl, 3 mM MgCl2, 100 µM ethylenediaminetetraacetic acid 
(EDTA), 10 mM βME, 50 µM GDP and protease inhibitors (1 µM leupeptin, 1 mM lima 
bean trypsin inhibitor, 1 mM PMSF and 1mM TPCK) and incubated with lysozyme 
(1 mg/ml) for ~30min. DNase was added to a final concentration of 5 µg/ml in the 
presence of 1mM MgSO4. The cells were further lysed by sonication and the lysate was 
ultracentrifuged at 40000 rpm for 45 min. The supernatant was loaded on a Ni-NTA 
column pre-equilibrated with buffer A (20 mM HEPES pH 8.0, 100 mM NaCl, 1 mM 
MgCl2, 50 µM GDP and 10 mM βME). The column was washed with 200 ml of buffer A 
followed by 100 ml of buffer B (buffer A with 300 mM NaCl and 10 mM imidazole). 
MBP tagged Gαq or GαqΔN was eluted with buffer A supplemented with 150 mM 
imidazole. Typically, 1-liter culture yielded 20 mgs of MBP-fusion protein. The eluted 
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protein was cleaved with 2% (w/w) tobacco etch virus (TEV) and dialysed against buffer 
A overnight (Fig. 2.2, samples 1-2). The dialysed protein was run on a 2nd Ni column 
(equilibrated with buffer A) to purify cleaved untagged Gαq.  The column was washed 
with 2-3 column volumes of buffer A and eluted with buffer A supplemented with 150 
mM imidazole (Fig. 2.2, samples 3-5). The flow-through and wash samples were pooled 
and concentrated using a Centriprep 30K concentrator and loaded on tandem S200 
Superdex gel-filtration columns. Purified Gαq was aggregated and eluted in the void 
volume (data not shown).  
  
 
 
Figure 2.2: SDS-PAGE of samples from Gαq purification from E. coli. 1. Ni-Column 
Eluate (MBP-Gαq) 2. Post-TEV, sample after TEV digestion of MBP-Gαq 3. Flow 
through from the run of the Post-TEV sample on a 2nd Ni-Column 4. Wash from the 2nd 
Ni-Column 5. Bump from 2nd Ni-Column.  
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The results of our Gαq purification from E.coli is consistent with an earlier report of 
failed purification of recombinant Gαq in bacterial expression systems (Hepler, Kozasa et 
al. 1993; Hepler, Kozasa et al. 1994). Hepler et al also reported a purification scheme for 
Gαq from Sf9 cells using recombinant baculovirus. When Gαq was expressed alone, a 
majority of Gαq was cytosolic; gel-filtration revealed that most of the cytosolic and 
membrane extracted protein was inactive and aggregated. To avoid this problem, they 
co-expressed Gαq with Gβ2 and Gγ2 as heterotrimer and purified Gαq from cholate-
extracted membranes of Sf9 cells. Although this approach yielded functional protein that 
could bind GTPγS and activate PLCβ, the yields were poor; ~125 µg of functional 
recombinant Gαq from 12 liter culture of infected Sf9 cells.  
 
Gα i/q Chimera 
 
Chimeras of Gα subunits with Gαi have been used for improved protein expression (Slep, 
Kercher et al. 2001; Chen, Singer et al. 2005; Kreutz, Yau et al. 2006). The Kozasa Lab 
(University of Illinois, Chicago) has generated chimeric versions of Gαq to improve the 
yields of soluble and Gαq for structural studies (Fig. 2.3).  Expressed Gαi/q protein 
consists of an N-terminal hexahistidine (His6) tag followed by TEV protease site, the N-
terminal 1-28 residues of Gαi, an engineered Arg and Ser linker, then residues (37-359) 
of Gαq. We also expressed a longer Gαq construct as a chimera, Gαi/q Long (T1), which  
consists of an N-terminal His6 tag, followed by residues (1-28) of Gαi,  a TEV protease 
site, then residues (2-359) of Gαq.  
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Figure 2.3:  Schematic Representation of Gα i/q and Gα i/qLong(T1)  chimera.  
 
 
Whereas wild type Gαi is myristoylated at Gly2, the hexahistidine tag at the N-terminal 
end of the Gαi/q chimera prevents myristoylation. Gαi/q also lacks the palmitoylation sites 
(Cys9, Cys10) corresponding to Gαq. Thus, Gαi/q was expected to express as a soluble 
protein (lacking any post-translational lipid modification) that can be extracted from the 
cytosolic fraction of High5 cells. We co-expressed Gαi/q with Gβγ and purified the 
complex as a heterotrimer.  
 
Expression and purification of Gα i/qβγ s  
 
Baculoviruses for expression of Gαi/q, bovine Gβ1 and bovine His6-tagged soluble Gγ2 
(C68S mutant, henceforth referred to as Gγs) were used to co-infect High 5 insect cells 
and the culture was harvested 36-48 hours after infection.  All purification steps were 
performed at 4°C.  The cell pellet was resuspended in lysis buffer containing 20 mM 
HEPES pH 8.0, 100 mM NaCl, 3 mM MgCl2, 100 µM EDTA, 10 mM βME, 50 µM GDP 
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and protease inhibitors (1 µM leupeptin, 1 mM lima bean trypsin inhibitor, 1 mM PMSF 
and 1mM TPCK) and lysed with a dounce homogenizer followed by sonication.  The 
supernatant was isolated by ultracentrifugation for 40 min at 186,000xg, then filtered and 
diluted to a final protein concentration of 5 mg/ml with buffer A (20 mM HEPES pH 8.0, 
100 mM NaCl, 1mM MgCl2, 50 µM GDP and 10 mM βME) and loaded onto a 10 ml Ni-
NTA column pre-equilibrated with buffer A.  The column was washed with 200 ml of 
buffer A followed by 100 ml of buffer B (buffer A with 300 mM NaCl and 10 mM 
imidazole).  Gαi/qβγs and free Gβγs were eluted using buffer A supplemented with 
150 mM imidazole.  The eluate was treated with 2% w/w TEV protease and dialyzed 
against buffer A, in which 2 mM dithiothreitol (DTT) was substituted for βME.  
Cleavage of the His6 tag from the amino terminus of Gαi/q was confirmed by SDS-PAGE 
(Fig. 2.4).  The protein was concentrated using a 50 kDa Centriprep (Millipore) to about 
20 mg/ml, and Gαi/qβγs was purified from excess Gβγs on two tandem Superdex S200 
gel-filtration columns (Amersham Pharmacia Biotech) pre-equilibrated in buffer E, with 
2 mM DTT in place of βME.  Peak fractions (0.3 ml each) were analyzed by SDS-PAGE 
(Fig. 2.5) and fractions containing Gαi/qβγs were pooled and concentrated on a Centricon 
YM-50 to 15-20 mg/ml.  This protocol resulted in approximately 1 mg of purified 
Gαi/qβγs from 1 liter of culture. A similar purification scheme yielded 2.5 mg of long (T1) 
Gαi/qGβγs from 5 liter of culture. 
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Figure 2.4: Purification of Gα i/qGβγ s heterotrimer. Gαi/q was isolated as a part of 
Gαi/qGβγs heterotrimer. The N-terminal His-tag on Gαi/q was cleaved by TEV protease 
and complete digestion was confirmed by SDS-PAGE. 
 
Figure 2.5: Gel-filtration of the Gα i/qGβγ s heterotrimer. Pure Gαi/qGβγs was purified 
from excess Gβγs by gel filtration and peaks factions were analyzed by SDS-PAGE 
(inset).  
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Purification of GRK2:  
 
GRK2 S670A was purified as described before (Lodowski, Barnhill et al. 2003). The 
S670A mutation of GRK2 removes a MAP kinase phosphorylation site (Pitcher, Tesmer 
et al. 1999). A Gαq insensitive mutant of GRK2 (D110A) was made in the above 
construct and purified using the same protocol.  
 
Purification of Gα i/q- GRK2 complex 
 
The Gαi/q-GRK2 complex was formed by mixing pure Gαi/qβγs (2 mg) with bovine 
GRK2 (1.8 mg of the S670A mutant) in 500 µl activation buffer (20 mM HEPES pH 8.0, 
200 mM NaCl, 10 mM MgCl2, 2 mM DTT, 50 µM GDP, 10 mM NaF and 30 µM AlCl3) 
and then incubating at 30 °C for 15 min.  The sample was injected onto two-tandem S200 
Superdex gel-filtration columns pre-equilibrated in activation buffer. Proteins were 
filtered through a 0.45 µm filter (Pall, MI) prior to loading. 0.3 ml fractions were 
collected during gel-filtration and the peak fractions were analyzed by SDS-PAGE and 
visualized with Coomassie blue staining. The fractions containing Gαi/q-GRK2 and Gβγs 
were separately pooled and concentrated to 10-15 mg/ml using Centricon YM-50.  
 
Mixing Gαi/qβγs with GDP·AlF4
- in the presence of GRK2 resulted in the formation of a 
stable 1:1 complex of Gαi/q-GRK2 that could be isolated by gel filtration (Fig. 2.6).  
Omission of AlF4- resulted in no complex formation with GRK2.  Notably, GRK2 did not 
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require detergent to liberate activated Gαq from Gβγ, whereas in the absence of GRK2, 
detergent is required to dissociate Gαi/qβγ at the protein concentrations used.  Free Gβγs 
was a byproduct of the reaction, suggesting that Gαq and Gβγ have little affinity for each 
other upon interaction with GRK2.  Our inability to observe tight binding of Gβγs to 
GRK2 itself was as reported previously, only wild-type (geranylgeranylated) Gβγ (Gβγwt) 
in detergent micelles binds GRK2 with high enough affinity for complex isolation by gel 
filtration (Lodowski, Pitcher et al. 2003).  Nevertheless, a substoichiometric amount of 
 Gβγs coelutes with the peak fractions for the Gαi/q-GRK2 complex (Fig. 2.6). We next 
attempted to form the heterotetrameric complex Gαi/q-GRK2-Gβγ complex using wild-
type Gβγ in detergent micelles (Fig 2.7).  
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Figure 2.6: Formation of a Gα i/q-GRK2 complex.  (A) Peak fractions from gel 
filtration analysis correspond to the Gαi/q-GRK2 complex (1), excess Gαi/qβγs 
heterotrimer (2), and GRK2-displaced Gβγs (3), as determined by SDS-PAGE.  Note that 
a sub-stoichiometric amount of Gβγs coelutes with the peak fractions for the Gαi/q-GRK2 
complex in peak 1, and that, at the high concentrations used in this experiment, AlF4- 
alone is not sufficient to disrupt the Gαi/qβγs heterotrimer in peak 2. (B) In small-scale 
reactions performed in the absence of AlF4-, a complex was not observed, with peak 
fractions corresponding to free GRK2 (1) and Gαi/qβγs (2). 
A 
B 
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Purification of Gα i/q- GRK2- Gβγ  complex  
 
To form a Gαi/q-GRK2-Gβγ heterotetrameric complex, pure Gαi/qβγs (1.8 mg) was mixed 
with GRK2 (1.6 mg) in 200 µl activation buffer that contained 1mM ATP.  The reaction 
mixture was incubated at 30ºC for 15 min, then on ice for 5 min, and then supplemented 
with 10 mM CHAPS followed by 1.6 mg of wild-type, geranylgeranylated Gβγ (Gβ1γ2wt).   
 
Figure 2.7: Formation of a Gα i/q-GRK2-Gβγwt complex. A binding reaction for 
creating the Gαi/q-GRK2 complex was supplemented on ice with 10 mM CHAPS and 
geranylgeranylated wild-type Gβγ and incubated for 1 hr before gel-filtration. ‘L’ denotes 
SDS-PAGE analysis of the sample loaded onto the column.  Peak 1, which appears to 
consist of multiple peaks, is interpreted to be both fully and partially associated Gαi/q- 
GRK2- Gβγ.  Peaks 2-4 correspond to excess heterotrimer (possibly consisting of both 
Gαi/qβγs and Gαi/qβγwt), CHAPS-associated Gβγwt, and soluble Gβγs, respectively.  
  
The reaction mixture was incubated on ice for 1 hr and injected onto gel-filtration 
columns pre-equilibrated in the activation buffer containing 50 mM NaCl, 1 mM ATP 
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and 10 mM CHAPS. Thus, when the Gαi/q-GRK2 complex was supplemented with 10 
mM CHAPS and 2 molar equivalents of the geranylgeranylated form of Gβγ, a stable 
1:1:1 complex of Gαq-GRK2-Gβγ  could be isolated by gel filtration (Fig. 2.7).  Thus, the 
binding of Gαi/q and Gβγ to GRK2 are mutually compatible and are of reasonably high 
affinity, suggesting that an analogous Gαq-GRK2-Gβγ complex will form in the vicinity 
of Gαq-coupled receptors after hormone activation.  If so, then this complex serves as a 
paradigm for phosphorylation-independent desensitization, wherein the downstream 
targets of Gαq and Gβγ are effectively blocked by GRK2, irrespective of its intrinsic 
kinase activity. 
 
Crystallization of the Gα i/q-GRK2-Gβγ  complex 
 
 
Our initial attempts to crystallize Gαi/q βγ heterotrimer (in the presence of GDP or 
GDP·AlF4-) and Gαi/q-GRK2 complex did not yield any crystals.  Although wild-type 
(geranylgeranylated) Gβγ was required to form a stoichiometric complex of 
Gαi/q-GRK2-Gβγ that could be isolated by size exclusion chromatography, we tried to 
crystallize the heterotetrameric complex using Gαi/q-GRK2 supplemented with Gβγs. A 
500-µl binding reaction was performed in which 1.4 mg GRK2 was incubated with 2.7 
mg of a TEV-treated mixture of βγs and Gαi/qβγs (approximately 1 mg pure Gαi/qβγs) in 
20 mM HEPES, pH 8.0, 100 mM NaCl, 10 mM MgCl2, 2 mM DTT, 5 mM ATP, 50 µM 
GDP, 10 mM NaF and 30 µM AlCl3.  After 15 min at 30° C, the reaction was placed on 
ice for 30 min, then filtered and injected onto gel-filtration columns pre-equilibrated with 
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the binding buffer with ATP reduced to 1 mM and MgCl2 reduced to 5 mM.  A 1.5 molar 
excess of Gβγs was added to pooled fractions containing Gαi/q-GRK2, and concentrated 
to 10-15 mg/ml with a Centricon YM-50.  
 
 
Figure 2.8: Crystallization of the Gα i/q-GRK2-Gβγ s complex.  (A) SDS-PAGE 
analysis of the complex used to form the crystals shown in panel B.  Bands were 
visualized with Coomassie Brilliant Blue.  The relative positions of molecular weight 
markers are shown on the left.  Gγs runs at the dye front of the gel.  (B) Cluster of the 
Gαi/q-GRK2-Gβγs crystals that formed with well solution 9% PEG 8K, 1M NaCl and 0.1 
M MES, pH 6.5.  These crystals grew to maximum dimensions of 400 x 50 x 50 µm.  
Slightly larger crystals used for structural analysis were grown similarly but with NaCl 
reduced to 800 mM. 
 
Crystals of the Gαi/q-GRK2-Gβγs complex were grown at 4 °C by hanging drop vapor 
diffusion method in which the concentrated protein was mixed 1:1 with the well solution 
(Fig. 2.8).  Diffraction data were analyzed for a crystal in which the well solution was 9% 
PEG 8K, 0.8 M NaCl, and 0.1 M MES pH 6.5.  The micelle-based Gαi/q-GRK2-Gβγwt 
A B 
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complex was also crystallized; but these crystals are too small to permit structural 
analysis. 
 
Table 1: Gα i/q-GRK2-Gβγ s Crystallization data and refinement statistics  
Space Group P21 
Cell constants (Å, ˚) a = 65.5 
b = 130.3 
c = 124.0 
β = 95.6 
No. of crystals  1 
Wavelength (Å)  1.116 
Dmin (Å, a*, b*, c*) * 3.5, 4.5, 3.0 
Unique reflections  22539 
Average redundancy  5.7 
Rsym† (%)  10.6 (64.3) ‡ 
Completeness (%)*  60.0 (4.8) ‡ 
<I>/<σI>  22.4 (4.3) ‡ 
Res. range for refinement (Å) *  47-3.1 
Total reflections used  37811 
No. protein atoms  10839 
No. ligand and water atoms  39 
R.m.s.d. bond lengths (Å)  0.006 
R.m.s.d. bond angles (˚)  0.92 
R (%)§ 23.6 
Rwork|| (%)  24.2 
Rfree¶ (%)  29.2 
* Due to anisotropy, data beyond these limits were excluded for the purposes of generating interpretable scaling 
statistics.  However, the untruncated data set was used in refinement.  Without omitting any data, Rsym = 13.3%, 
Completeness = 100%, and <I>/<σI> = 13.5. 
† Rsym = ∑h∑i |I(h)-I(h)i| / ∑h∑iI(h)i where I(h) is the mean intensity after rejections.  Data was truncated at 3.1 Å. 
‡ Numbers in parentheses correspond to the highest resolution shell of data, which was 3.2-3.1 Å. 
§ For all reflections; Rfree was not used for the last three rounds of refinement. 
|| Rwork = ∑h ||Fobs(h)|-|Fcalc(h)|| / ∑h|Fobs(h)|; no I/σ cutoff was used during refinement. 
¶ 5% of the truncated data set was excluded from refinement to calculate Rfree. 
 
The Gαi/q-GRK2-Gβγs complex crystallized in space group P21 and the crystals diffracted 
anisotropically to beyond 3.0 Å spacings in the c* direction at ALS Beam Line 8.3.1.  
The structure was solved by molecular replacement using Gβ1γ2, GRK2 (both from PDB 
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entry 1OMW) and a homology model of Gαq as consecutive search models, with the 
asymmetric unit containing one heterotetrameric complex.  The model was built using the 
program O, and refined using simulated annealing in CNS_SOLVE and then TLS and 
restrained refinement in REFMAC5.  The final model contains residues 28 to 475 and 
492 to 667 of bovine GRK2 (out of 689 total), 2 to 340 of bovine Gβ1  (out of 340), 4 to 
67 of bovine Gγ2 (out of 68), and 38 to 354 of mouse Gαq (from the present 37 to 359 
amino acids), with no chimeric residues of Gα observed (Tesmer, Kawano et al. 2005). 
 
RESULTS & DISCUSSION 
 
Quaternary structure of the Gα i/q-GRK2-Gβγ  complex 
 
The crystal structure of Gαi/q-GRK2-Gβγ complex is the first structure of a member of 
Gαq subfamily. In the Gαi/q- GRK2- Gβγ structure, GRK2 serves as a scaffold binding 
activated Gαi/q and Gβγ subunits with its RH domain and PH domain, respectively (Fig. 
2.9). Gαi/q is in active conformation bound to GDP, Mg2+ and AlF4- and the conformation 
of the switch regions is similar to other activated Gα subunits (Fig. 2.12).  
 
The conformation of GRK2-Gβγ in the Gαi/q bound conformation is similar to that in the 
structure of GRK2-Gβγ alone and the PH domain - Gβγ interface is essentially the same 
in both structures (Lodowski, Pitcher et al. 2003). However, Gαi/q is in an unusual 
orientation with respect to the membrane surface when compared to its orientation in 
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Gαβγ heterotrimer (Fig. 2.10) (Wall, Coleman et al. 1995; Lambright, Sondek et al. 
1996). There are several markers on the Gαi/q-GRK2-Gβγ complex that enable us to 
approximately predict where the membrane surface would be. These include the patch of 
basic residues on Gβ, the posttranslational lipid modified site on Gγ (gerenylgerenylation 
at Cys68), the N-terminal helix of Gαq that is basic and also gets palmitoylated at Cys9 
and Cys10, residues in the PH domain known to bind membrane-bound anionic 
phospholipids, the first observed N-terminal residue of GRK2 (Ala28) that follows the 
phospholipid and/or receptor binding in GRKs and a basic electrostatic flat membrane-
proximal surface on GRK2 (Lodowski, Pitcher et al. 2003).   
 
In the GRK2 bound conformation, Gαq is dramatically rotated by ~105° from its 
predicted position in an inactive GDP and Gβγ bound conformation (Fig. 2.10).  The 
regions on Gαq that are expected to contact the membrane surface, namely the N-terminal 
helix and C-terminus are rotated away from the membrane in the GRK2 bound 
conformation; the switch regions I and II, the αB-αC loop and the linker 1 regions are 
facing the membrane, although ~25 Å apart (Fig. 2.11). Gβγ also undergoes a ~20° 
rotation when compared to its position in the inactive Gαβγ heterotrimer (modeled based 
on Gαi1βγ structure). The Gαi/q-GRK2-Gβγ structure provides a snapshot of activated Gα 
and Gβγ subunits at the membrane surface.  In order to see if the conformation of 
activated Gα in Gαi/q-GRK2-Gβγ complex is consistent with other Gα-effector 
complexes (Tesmer, Sunahara et al. 1997; Slep, Kercher et al. 2001; Chen, Singer et al. 
2005), we did structural superposition of these complexes. While PDEγ bound Gαt and 
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p115RhoGEF bound Gα13 is compatible with a similar Gα orientation, AC bound Gαs is 
not (Fig. 2.9 & 1.8). 
 
Figure 2.9: Quaternary structure of Gα i/q-GRK2-Gβγ  complex. GRK2 binds 
activated Gαq and Gβγ subunits with its RH and PH domain, respectively. Gαi/q is shown 
in cyan with light-orange β strands. The switch regions of Gαi/q are colored red. 
GDP·Mg2+·AlF4- is shown in ball and stick model. The kinase domain of GRK2 is shown 
in yellow with lime β strands, RH domain is shown in purple and PH domain is sand. Gβ 
and Gγ subunits are shown in blue and green, respectively. N and C refers to observed 
amino and carboxyl termini of respective proteins. α5 and α6 helix of GRK2 RH domain 
contacts the classic effector-binding site of Gαq subunit.   
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Figure 2.11: Re-orientation of activated Gαq upon binding GRK2. The inactive GDP 
bound conformation of Gα is based on a homology model of Gαqβγ, shown in Fig. 2.10. 
The active GDP·Mg2+·AlF4- conformation of Gα is from the Gαi/q-GRK2-Gβγ structure. 
The Gα subunits were positioned by centering the Gβγ subunits in the respective two 
complexes. Upon binding GRK2, Gαq undergoes a ~105° rotation compared to its 
orientation in Gαqβγ complex. The switch I and II, αB-αC loop and the linker 1 region 
are most proximal to the membrane, ~ 25Å apart. Arg38, the most N-terminal residue of 
Gαq seen in Gαi/q-GRK2-Gβγ structure is expected to interact with membrane in Gαβγ 
heterotrimer, but is displaced away by ~30Å from the membrane in the active GRK2 
bound conformation. The N-terminus of Gαq in a helical conformation is long enough 
(37 residues = ~55 Å) to place the palmitoylation sites (C9 and C10) at the membrane. 
Arg38 in the inactive and active conformation are ~80 Å apart. If activated Gα and Gβγ 
were derived from the same heterotrimer, the N-terminal helix would fall short of 
contacting Gβγ. Thus it appears that activated Gα and Gβγ are completely dissociated 
from one another in the GRK2 bound conformation. The coloring scheme is similar to 
Fig. 2.9. 
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Figure 2.12: Comparison of the active sites of Gαq and Gα i1. The GDP·Mg2+·AlF4- 
active sites of Gαi1 and Gαq is shown in A and B respectively. The conformation of 
switch regions I, II and III and that of the important catalytic residues (Q204, R178, S47 
and T181, numbers as in Gαi1) are very similar in both Gαi1 and Gαq.      
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The Gαq-GRK2 Interface  
 
The interface of Gαi/q-GRK2 involves the classic effector-binding site of Gα, namely the 
α2 helix (switch II), α3 helix and the α3-β5 loop of Gαq (Fig. 2.13). Gαq binds the α5 
and α6 helices of GRK2 RH domain, as identified by mutagenesis studies (Sterne-Marr, 
Tesmer et al. 2003). In particular, Gαq-Tyr261 forms hydrogen bonds with GRK2- 
Asp110 and Arg106 and also the side chain of Thr260 hydrogen bonds to side chain of 
GRK2- Gln133. Residues GRK2- Met114, Leu117, Leu118 and Cys120 pack in the cleft 
between the α2 and α3 helices of Gαq and form hydrophobic interactions. Mutation of 
GRK2- Arg106, Phe109, Asp110 and Leu118 were shown to abolish Gαq binding to 
GRK2 RH domain (Day, Carman et al. 2003; Sterne-Marr, Tesmer et al. 2003). Also, 
D110A mutation in GRK2 reduces GRK2-mediated phosphorylation-independent 
desensitization in hippocampal neurons (Willets, Nahorski et al. 2005). This is a novel 
Gα binding interface on the RH domain and is much different from the classic Gα 
binding site on RGS proteins such as RGS4 and RGS9 (Tesmer, Berman et al. 1997; 
Slep, Kercher et al. 2001) (Fig. 1.7). Gαi/q-GRK2 interface buries ~1700 Å2 of accessible 
surface area. 
 
GRK2 interacting residues on Gαq are analogous to residues on Gαs and Gαt that interact 
with AC and PDEγ, respectively (Fig. 2.14) (Tesmer, Sunahara et al. 1997; Slep, Kercher 
et al. 2001). The RH domain of GRK2 binds Gαq more like an effector than a classic 
GAP RGS domain of RGS4. This is consistent with the data that (i) GRK2 can bind both 
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GTPγS and GDP·AlF4- activated Gαq, (ii) GRK2 has no significant GAP activity of Gαq 
and (iii) GRK2 antagonizes Gαq stimulated PLCβ activity (Carman, Parent et al. 1999).   
 
 
Figure 2.13: Gαq-GRK2 interface: GRK2 binds Gαq like an effector. The α5 and α6 
helices of GRK2 RH domain are shown as a cartoon ribbons in purple. The α2 (switch II) 
and α3 helices of Gαq are shown as Cα traces, colored in red and cyan respectively.  
Amino acid residues in the interface are represented by ball and stick model. N, O and S 
atoms are colored blue, pale red and yellow, respectively. 
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Figure 2.14: Sequence alignment of the switch region and α3/β5 sequence of 
members of Gαq/11 subfamily, Gα i1, Gα t, Gα s and Gα13 subunits. The switch regions 
are shown in boxes. The secondary structures are shown as cylinders for α-helices and 
arrows for β-strands. The residues that contact effector are colored green and those that 
contact GAP domain are colored red. Residues that contact both effector and GAP 
domains are colored in purple. Pale red or pale green refers to GAP/effector contacting 
residues that were chimeric in the respective crystal structures solved (Tesmer, Berman et 
al. 1997; Tesmer, Sunahara et al. 1997; Slep, Kercher et al. 2001; Chen, Singer et al. 
2005; Tesmer, Kawano et al. 2005). The sequences are those of rat Gαi1 GI:121020, 
bovine Gαt GI: 121031, bovine Gαs GI: 121000, mouse Gαq GI: 84662745 and mouse 
Gα13 GI: 120984, mouse Gα11 GI: 6754004,  mouse Gα14 GI: 160298199 and human 
Gα16 GI: 182891.  
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Mutational Analysis of Gαq residues 
 
Mutants in Gαq (R214A, R256G, T257E, Y261F, Y261L, P262K and W263D) were 
made in pCMV5 vector expressing WT Gαq and expressed in HEK 293 cells. Pull-down 
assays were performed to test the binding of WT or mutant Gαq with GRK2 in activation-
dependent manner (GDP Vs GDP·AlF4-). While Gαq-R214A had no effect and Gαq -
R256G had reduced binding, T257E, Y261F, Y261L, P262K and W263D mutations in 
Gαq completely abolished binding to GRK2 (Fig. 2.15). The complete loss of binding by 
Y261F mutant to GRK2 shows the importance of hydrogen bonding between Gαq-Y261 
and GRK2-D110/R106.   
 
In other Gα family members, the residue equivalent to P262 in Gαq (and Gα11, Gα14, 
Gα16) is substituted by lysine or arginine (Fig. 2.14). Loss of GRK2 binding by Gαq 
mutant P262K explains the specificity of GRK2 to Gαq subfamily versus other Gα 
subunits. Gα16 of Gαq subfamily does not interact with GRK2 (Day, Carman et al. 2003).  
Gαq-Y261L and R256G represent substitution of these residues to equivalent residues in 
Gα16. Reduced GRK2 binding by R256G and complete elimination of binding by Y261L 
explains the molecular mechanism that dictates Gαq /Gα11 / Gα14 specificity to GRK2 
binding. Mutational analysis of Gαq residues involved in binding GRK2 was performed 
at our collaborator Kozasa’s Lab (Tesmer, Kawano et al. 2005) 
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Figure 2.15: Mutational analysis of Gαq residues that directly interact with GRK2. 
Lysates of HEK293 cells expressing Gαq mutants were subject to trypsin protection assay 
in the presence and absence of AlF4- and immunoblotted with Gαq specific antibody. The 
I217D mutant could not be protected from trypsin digestion and hence judged 
nonfunctional (upper left). All Gαq mutants expressed to similar levels as wild-type 
(lower left). Pull-down assays were performed by incubating lysates with 40 nM 
glutathione S-transferase (GST) fusion protein of GRK2-RH, RGS3 (amino acids 313 to 
519), or RGS4 either in the presence or absence of AlF4-. Bound Gαq was detected with 
Gαq-specific antibody.  
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Implications of Gα i/q-GRK2-Gβγ  structure 
 
The mutations in Gαq that affected GRK2 binding had no effect on RGS4/RGS3 binding 
(Tesmer, Kawano et al. 2005).  Thus the RH domain of GRK2 binds Gαq in a surface that 
is different from the surface used by classic RGS proteins such as RGS4. We then 
superimposed the structure of Gαi1-RGS4 complex on Gαi/q-GRK2-Gβγ complex and 
modeled RGS4 in complex with Gαi/q-GRK2 (Fig. 2.16). Indeed, RGS4 has no obvious 
steric overlap with GRK2 binding to Gαq. The position of the modeled RGS4 is 
consistent with the predicted membrane interacting surface of RGS4, which includes its 
palmitoylation site and amphipathic helix at the N-terminus and the phospholipid 
interacting α4-α5 loop (Popov, Krishna et al. 2000) (Tu, Popov et al. 1999). Thus it 
appears that Gαq can interact with two RH domains, one at the effector site (GRK2) and 
other at the GAP site (RGS4).  The structure supports the formation of higher order 
signaling complex involving GPCRs, GRK2, Gαq, Gβγ and RGS proteins at the 
membrane surface.   
 
Synergistic association of effector and GAPs on Gα subunit has been shown before in the 
visual signaling pathway, wherein simultaneous association of effector (PDEγ) and GAP 
(RGS9) on Gαt is required for physiological rates of signal responses (He, Cowan et al. 
1998; Slep, Kercher et al. 2001). PDEγ enhances RGS9-mediated acceleration of GTP 
hydrolysis on Gαt. Thus, segregation of effector and GAP binding sites on Gαt enables 
phototransduction to occur, before GAP activity is brought to bear to terminate the signal, 
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preventing a potential short-circuit. Drawing parallels to Gαq signaling, the effector-like 
interaction of GRK2 and the model of RGS4 docked on Gαq-GRK2 raises the question if 
GRK2 can itself function as a Gαq effector. Interestingly, GRK2 is shown to 
phosphorylate downstream targets such as insulin receptor substrate IRS-1, ezrin and p38 
MAP kinase in response to Gq-coupled receptors (Cant and Pitcher 2005; Usui, Imamura 
et al. 2005; Peregrin, Jurado-Pueyo et al. 2006).  Its possible that phosphorylation of 
these downstream targets is initiated by direct interaction of Gαq with GRK2 upon 
activation of Gq-coupled receptors. In Chapter 4, we discuss our biophysical and kinetic 
studies that demonstrate the formation of a RGS-Gαq-GRK2 ternary complex. Similar to 
the visual signaling pathway, we show that effector coupling of Gαq is also modulated by 
RGS proteins such as RGS2 and RGS4.  
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Figure 2.16: Model of RGS4 docked on the Gαq-GRK2 complex. The structure of 
Gαi/q-GRK2-Gβγ (PDB ID: 2bcj) was superimposed on Gαi of Gαi-RGS4 structure (PDB ID: 
1agr). There is no obvious steric overlap between the docked-RGS4 and GRK2 binding sites on 
Gαq. The PH domain of GRK2 is not shown for clarity. Gαq is colored cyan with orange 
β-strands and the three switch regions (SwI, SwII and SwIII) are colored in red.  GDP bound to 
Gα subunits is shown as spheres. Mg2+ (black) and AlF4- (sand and light blue) are bound to the 
active site of Gα. The kinase domain and RH domain of GRK2 is colored yellow and purple 
respectively. RGS4 is colored in dark green. The predicted membrane surface is parallel to the 
top of the figure. 
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Chapter 3 
 
Structural Insights into Gαq 
Interactions with p63RhoGEF to 
Activate RhoA 
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BACKGROUND AND RESEARCH PLAN 
 
Rho GTPases belong to the Ras superfamily of small GTPases (~21 kDa). Activation of 
Rho GTPases is triggered by several cell surface receptors such as cytokine and tyrosine 
kinase receptors as well as GPCRs. RhoA, Rac1 and Cdc42 represent the first identified 
members of Rho GTPases that are implicated in the formation of filamentous actin 
structures in fibroblasts, namely stress fibers, lamellopodia/membrane ruffles and 
fillopodia, respectively. There are ~22 of Rho GTPases identified now in the human 
genome. The family of Rho GTPases is known to link membrane receptors to a number 
of physiological processes such as cell growth, proliferation, adhesion and migration, 
axon guidance, gene transcription regulation and actin cytoskeleton organization. Rho 
signaling is implicated in tumorigenesis, tumor invasion and metastasis (Hall 1998) 
(Mackay and Hall 1998; Rossman, Der et al. 2005) (Sahai and Marshall 2002) (Schmidt 
and Hall 2002).  
 
The Rho GTPase domain is similar to the Ras-like GTPase domain of heterotrimeric Gα 
subunits discussed in Chapter 1 (Fig. 3.1 & 1.2). They have similar conserved sequence 
elements for nucleotide and Mg2+ binding and the conformation of their switch regions 
vary depending on the form of nucleotide (GDP/GTP) bound (Vetter and Wittinghofer 
2001). Three classes of proteins regulate the cycling of Rho GTPases between GDP and 
GTP bound states. RhoGEFs stimulate the exchange of GDP for GTP to generate active 
GTP bound Rho GTPases. GAPs enhance the rate of GTP hydrolysis on Rho GTPases. 
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Rho guanine nucleotide dissociation inhibitors (Rho-GDIs) stabilize the inactive GDP 
bound Rho GTPases. Thus GEFs, GAPs and GDIs tightly modulate the signaling of 
Rho GTPases to downstream effectors. (Bos, Rehmann et al. 2007); (Lutz, Freichel-
Blomquist et al. 2004).  
 
 
Figure 3.1: Comparison of the GDP and GTPγS bound forms of RhoA. RhoA is 
shown in green with the switch regions I and II in red. The nucleotide (GDP or GTPγS) 
and Mg2+ ion are shown as a ball and stick model. The conformational differences 
between the GDP and GTPγS bound RhoA are mostly confined to the switch regions.  
 
The first identified mammalian RhoGEF was Dbl, a transforming gene in diffuse B-cell 
lymphoma cells that activates Cdc42 (Hart, Eva et al. 1991). A conserved domain called 
Dbl Homology (DH) domain was identified in Dbl that is responsible for its GEF activity 
on Cdc42. Since then, ~69 distinct RhoGEFs have been identified in the human genome 
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and they have varying degrees of specificity towards the various Rho GTPases. Most 
RhoGEFs have a ~200 amino acid DH domain followed by a C-terminal ~ 100 amino 
acid PH domain. While the DH domain is the catalytic domain necessary for GEF 
activity, the PH domain appears to modulate GEF activity by allosteric mechanisms or by 
direct interaction with Rho GTPase. The PH domain also binds phospholipids and 
mediates plasma membrane localization of some RhoGEFs. Most RhoGEFs have 
additional protein domains that reflect their unique cellular functions (Schmidt and Hall 
2002; Rossman, Der et al. 2005).  
 
Rho GTPases bind GDP or GTP with similar affinities in the nanomolar range and have 
slow dissociation rates for either nucleotide (Ihara, Muraguchi et al. 1998). RhoGEFs 
stimulate the exchange of GDP for GTP on Rho GTPases by facilitating the dissociation 
of GDP and Mg2+ and stabilizing the apo form of Rho GTPase. While the GEF-G protein 
complex does not favor the rebinding of GTP over GDP, GTP is preferentially loaded on 
Rho GTPase due to10 fold higher concentrations in vivo (Vetter and Wittinghofer 2001) 
(Schmidt and Hall 2002).  
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Figure 3.2: DH-PH domain of Dbs RhoGEF in complex with Cdc42. DH domains of 
RhoGEFs stabilize the nucleotide free conformation of Rho GTPases. The DH domain of 
Dbs is shown in yellow with the conserved regions CR1-3 colored in pink. The PH 
domain of Dbs is shown in purple. Cdc42 is shown in green with bright-orange colored 
strands. The switch regions I and II of Cdc42 are colored red. N and C refers to amino 
and carboxyl termini of proteins, respectively.  
 
Several structures of RhoGEFs and RhoGEFs bound to Rho GTPases have been 
determined. The DH domain forms an elongated α-helical bundle (Fig. 3.2). It consists of 
three conserved regions (CRs) that are involved in the Rho GTPase interface and 
mutations within these regions affect GEF activity. The switch 1 region of Rho GTPases 
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interacts with both CR1 and CR3, while switch II region mainly contacts CR3 and 
portions of the C-terminal α6-helix of the DH domain. CR2 sits at the back of CR1 and 
CR3, mainly stabilizing the helical bundle. A conserved glutamate (Glu639 in Dbs) in 
CR1, a conserved lysine (Lys774 in Dbs) in CR3 and a partially conserved asparagine in 
α6-helix of DH domain (Asn810 in Dbs) are crucial for the RhoGEF-GTPase interaction. 
Two critical changes occur at the nucleotide-binding pocket of Rho GTPase: insertion of 
the methyl group of Ala59 (in Cdc42) into the coordination site of the Mg2+ ion and an 
ionic interaction between Lys16 and Glu62 (in Cdc42). These changes essentially 
destabilize the binding sites of Mg2+ and β-phosphate of GDP to the Rho GTPase, 
favoring Mg2+ and GDP dissociation. The resulting RhoGEF-GTPase binary complex is 
now free to interact with the excess GTP·Mg2+ in cells (Hoffman and Cerione 2002; 
Erickson and Cerione 2004; Rossman, Der et al. 2005).  
 
The interaction of the PH domain with membrane-bound phospholipids may orient the 
associated DH domain so that it can properly bind prenylated RhoGTPases (Rossman, 
Der et al. 2005). While the overall domain structure of the PH domain is conserved 
among the RhoGEFs, its relative orientation with respect to the DH domain can vary. The 
PH domain orientation in Dbs, Tiam1, Intersectin, Leukaemia-associated Rho GEF 
(LARG), ITSN-L and N-Trio is similar as they pack against the α6-helix of the DH 
domain (Fig. 3.2). However, in Dbs-Cdc42, PDZ-RhoGEF-RhoA and LARG-RhoA 
structures, the PH domain also forms an interface with the DH domain bound 
Rho GTPase and contribute towards GEF activity. In Tiam1-Rac1 and ITSN-L-Cdc42 
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structures, the PH domain is oriented away from the bound GTPase (Worthylake, 
Rossman et al. 2000; Rossman, Worthylake et al. 2002; Derewenda, Oleksy et al. 2004; 
Kristelly, Gao et al. 2004). In the structure of DH/PH domain of Son of Sevenless (SOS) 
protein, the orientation of the PH domain is drastically different. It’s PH domain forms an 
interface with the GTPase binding site of the DH domain and inhibits nucleotide 
exchange activity on Rho GTPases (Soisson, Nimnual et al. 1998). Thus the PH domains 
in RhoGEFs can both positively and negatively regulate activity by diverse mechanisms 
that can be modulated by protein-protein interaction or by interaction with phospholipids.  
 
Gα12 and Gα13 activate a RH-RhoGEFs (p115RhoGEF, pdz-RhoGEF and LARG) by 
direct interaction with the RH domain of RH-RhoGEFs, which is present N-terminal to 
their DH/PH domains. Activated Gα12/13 recruits these RhoGEFs to the plasma membrane 
to activate RhoA (Fukuhara, Chikumi et al. 2001). Studies have identified that Gαq/11 and 
Gαq/11-coupled receptors can also signal to RhoA activation (Chikumi, Fukuhara et al. 
2002; Vogt, Grosse et al. 2003). p63RhoGEF was identified as a potent activator of 
RhoA in vitro, that also induces RhoA-dependent stress fiber formation in fibroblasts and 
cardiac myoblasts (Souchet, Portales-Casamar et al. 2002) . Activated Gαq/11 directly 
interacts with p63RhoGEF and enhances its GEF activity on RhoA. p63RhoGEF is a 
63 kDa protein of 580 amino acids in length, contains only a tandem DH and PH domains 
and lacks a RH domain that forms the Gα interaction site in Gα12/13 activated RhoGEFs 
(Fig. 3.3). The DH-PH domains of p63RhoGEF are most closely related in sequence to 
the RhoA-specific DH-PH domains present in the C-terminus of Trio and Duet (Fig. 3.4) 
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(Rossman, Der et al. 2005). It was demonstrated by co-immunoprecipitation assays that 
Gαq interacts with C-terminal half of p63RhoGEF (295-580), containing the PH domain 
(Lutz, Freichel-Blomquist et al. 2005).  
 
 
 
 
Figure 3.3: Primary structure of the Trio RhoGEF family- Trio, Duet and 
p63RhoGEF proteins.  SH3 (Src homology domain 3); Ig (immunoglobulin domain); F 
(fibronectin type-III domain).  
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Figure 3.4: Structure-based sequence alignment of p63RhoGEF with Trio family 
members and Dbs.  Secondary structure is represented using cylinders and arrows for α-
helices and β-strands, respectively (DH domain in yellow, and the PH domain in purple).  
Sequence numbering at the top corresponds to that of human p63RhoGEF. p63RhoGEF 
residues that contact Gαq ( ≥ 10 Å2 buried accessible surface area) are highlighted cyan, 
and those that contact RhoA are green.  Basic residues predicted to interact with the 
membrane bilayer are highlighted orange.  Residues that are disordered in the 
Gαi/q·p63RhoGEF·RhoA complex are colored grey.  In Dbs, the residues that form the 
interface between the DH and PH domains are highlighted purple or yellow, respectively.  
Contacts that do not involve the long β3-β4 loop of Dbs, which is structurally 
heterogeneous among the RhoGEFs, are boxed.  Red dots indicate residues in 
p63RhoGEF that were targeted by site-directed mutagenesis in this study.  Sequences 
correspond to human p63RhoGEF (GenBank ID NM_182947), human Duet (Q9Y2A5), 
human trio (Hs_Trio; AAC34245), C. elegans Trio (Ce_Trio; NP_001021496), D. 
melanogaster Trio isoform E (Dm_Trio; NP_728563) and mouse Dbs (Dbs; Q64096).  
Asterisks below the sequence indicate invariant residues in the Trio family of RhoGEFs 
(thus excluding Dbs).  
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In order to gain insight into the molecular mechanism of activation of p63RhoGEF by 
Gαq, we performed extensive biochemical and cell-based experiments and also 
determined the crystal structure of the Gαi/q-p63RhoGEF-RhoA complex (Lutz, 
Shankaranarayanan et al. 2007). Our results ultimately show that Gαq interacts with both 
the DH and PH domains of p63RhoGEF and thereby releases the auto-inhibited state of 
the catalytic DH domain.  We also show that Trio, Duet and p63RhoGEF are a family of 
Gαq effectors, which lead to the activation of RhoA, both in vitro and in intact cells.  
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MATERIALS & METHODS 
 
Cloning of p63RhoGEF constructs 
 
To determine the minimal elements of p63RhoGEF that mediate Gαq activation in vitro, 
we expressed fragments of p63RhoGEF spanning residues 149-338, 149-477 and 
149-580 (p63-149-477 and p63-149-580) in E. coli. p63-149-338 and p63-149-477 spans 
the residues homologous to the DH and DH-PH domains observed in the crystal structure 
of Dbs RhoGEF, respectively (Snyder, Worthylake et al. 2002; Worthylake, Rossman et 
al. 2004). p63-149-580 spans the entire region previously known to be important for Gαq 
binding and activation (Lutz, Freichel-Blomquist et al. 2005). p63-149-338, p63-149-477 
and p63-149-580 constructs were cloned into the pMALH10C2T vector. 
 
To precisely define the minimal fragment of p63RhoGEF required for Gαq binding, we 
also tested 72 constructs spanning residues 295 to the C-terminus for their ability to 
compete with p63-149-580 in binding Gαq. The 72 constructs of p63RhoGEF were 
produced using ligation-independent cloning into pMCSG9 vectors (Donnelly, Zhou et 
al. 2006) by the High-throughput protein lab in the Life Sciences Institute at University 
of Michigan. The proteins corresponding to the 72 constructs were over expressed and 
Ni2+-NTA purified in 96-well plates (C.Brown and J. Delproposto, in preparation). The 
p63-149-492, p63-149-502, Duet-219-558 and Trio- 1894-2232 were also cloned in 
pMCSG9 vectors.   
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Purification of p63RhoGEF 
 
The purification protocol for p63RhoGEF is adapted from that used for LARG (Kristelly, 
Earnest et al. 2003). Rosetta (DE3) pLysS cells transfected with RhoGEF 
(p63RhoGEF/Trio/Duet) expression vectors were grown in Terrific Broth media 
supplemented with 50 µg/mL carbenicillin at 37°C to an OD600 of 0.7 and expression 
was induced with 200 µg/mL isopropylthiogalactopyranoside at 20 °C.  Cell pellets were 
collected after 20 h by centrifugation at 7000 rpm for 10 min, and resuspended in “Buffer 
A” (20 mM HEPES pH 8.0, 300 mM NaCl, 10 mM β-ME, 10 mM imidazole pH 8.0) 
plus 0.3 mM EDTA, 1 uM leupeptin, 1 mM lima bean trypsin inhibitor, and 0.1 mM 
phenylmethylsulphonyl fluoride.  An Avestin EmulsiFlex-C3 homogenizer was used for 
lysis.  After ultracentrifugation at 40000 rpm for 45 min using a Beckman Type 45 Ti 
rotor, soluble fractions were loaded onto Ni-NTA Superflow (Qiagen) columns 
equilibrated with Buffer A.  The columns were washed with Buffer A plus 20 mM 
imidazole pH 8.0.  Protein was eluted with Buffer A plus 250 mM imidazole pH 8.0, and 
fractions containing fusion protein were dialyzed against 20 mM HEPES pH 8.0, 300 
mM NaCl, 10 mM β-ME in the presence of 2 % (w/w) TEV protease to cleave the N-
terminal MBP fusion (Fig. 3.5). MBP was removed by passing the dialysed protein 
through Ni-NTA Superflow columns, and the eluate containing the RhoGEF construct 
was concentrated in a Centriprep YM-30 (Millipore) and gel- filtered into 20 mM HEPES 
pH 8.0, 100 mM NaCl, 1 mM DTT on two tandem Superdex 200 10/300 GL columns. 
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Mutants of p63RhoGEF were generated by Quick-change mutagenesis kit and purified as 
described for WT protein. Human RhoA was produced as described previously (Kristelly, 
Gao et al. 2004). 
 
Gαi/q purification: 
 
His6-Gαi/q was purified on a Ni-NTA column as described for Gαi/qβγs with the following 
modifications.  Baculovirus-infected High 5 insect cells were harvested after 40 hr.  The 
Ni-column eluate was diluted 10-fold using Buffer A (20 mM HEPES pH 8.0, 50 mM 
NaCl, 2 mM DTT, 1 mM MgCl2, 50 µM GDP, 30 µM AlCl3 and 10 mM NaF) and then 
loaded on a Mono Q anion exchange column pre-equilibrated with Buffer A.  His6-Gαi/q 
was eluted in a 100 ml gradient of 50 mM to 600 mM NaCl in Buffer A. All steps were 
performed at 4 °C. Gαi/q containing fractions were identified by SDS-PAGE, pooled and 
treated with 2-4% TEV protease for 5 hrs to cleave the N-terminal His6-tag. Gαi/q was 
concentrated to 10 mg/ml in a Centriprep YM-30 and then loaded onto two Superdex 200 
gel-filtration columns pre-equilibrated with 20 mM HEPES pH 8.0, 200 mM NaCl, 5 mM 
DTT, 5 mM MgCl2, 50 µM GDP, 30 µM AlCl3 and 10 mM NaF.  Fractions containing 
pure Gαi/q are pooled (Fig. 3.6) and concentrated to 10 mg/ml using a Centricon YM-30 
and stored at -80 °C.  The yield of pure Gαi/q varied from 0.5 to 7 mg from 6 liter culture.  
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Figure 3.5: Purification of p63-149-502 from E.coli. p63-149-502 was expressed as a 
MBP fusion protein in Rosetta cells. The cells were harvested, lysed and the cell lysates 
were poured on a Ni-NTA column. A) Gel image showing the samples collected at 
various stages of Ni-NTA purification. 1: Load to Ni-NTA column, 2: flow-through/wash 
sample, 3. Eluate, 4: eluate after TEV digestion, 5: flow-through wash from the 2nd 
Ni-NTA column and 6: wash from the 2nd Ni-NTA column. p63-149-502 isolated in the 
flow through/wash fractions of the 2nd Ni-column was concentrated and gel-filtered. B) 
Gel image showing the peak fractions of p63-149-502 gel-filtration run. L- load to the 
gel-filtration column. M- Protein molecular weight markers.  
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Figure 3.6: Gel filtration of Gα i/q chimera. Activated Gαi/q purified by the Mono Q 
chromatography is further purified by gel-filtration using two tandem Sephadex S200 
columns. M- Protein molecular weight markers. L- Load to the gel-filtration column. 
 
 
 
Figure 3.7: A scheme depicting flow cytometry protein interaction assay. 
Biotinylated Gαi/q, immobilized on LumAvidin beads, was incubated with different 
concentrations of Alexaflour (AF) 532 labeled p63RhoGEF in a 96-well plate. Beads are 
drawn into the Luminex flow cytometer. As beads pass the lasers, the bead is excited and 
detected by one laser, and a second laser excites the associated AF532-p63RhoGEF. 
Protein-protein interaction is detected as the flow cytometer only measures bead-
associated fluorescence. 
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Flow cytometry protein interaction assay (FCPIA)  
 
The p63RhoGEF, Trio and Duet constructs were labeled with Alexa Fluor 532 
(excitation/emission maxima ~531/554 nm; Invitrogen) and mixed in various 
concentrations with xMap LumAvidin microspheres (Luminex) linked to biotinylated 
Gαi/q resuspended in 20 mM HEPES pH 8.0, 100 mM NaCl, 5 mM MgCl2, 0.1% lubrol, 
2 mM DTT, 1% BSA, 50 μM GDP ± (20 μM AlCl3, 10 mM NaF). Bead-associated 
fluorescence was measured in a Luminex 96-well plate bead analyzer (Fig. 3.7) (Roman, 
Talbot et al. 2007). The binding is reported as the median fluorescence intensity (MFI) 
values for each concentration of protein, and binding data were fitted to a single-phase 
hyperbola by GraphPad Prism.  For each binding curve, each concentration point was 
measured in duplicate.  When different proteins are assayed in the same reaction, they are 
not expected to saturate at the same MFI due to different efficiencies of fluorescent 
labeling.  
 
Fluorescence polarization assay of RhoA guanine nucleotide exchange  
 
Fluorescence polarization is a technique used to measure molecular orientation and 
mobility using polarized light and fluorescent tracer. When excited with linearly 
polarized light, fluorescent tracers bound to slowly rotating large molecular weight 
molecules get more polarized compared to those bound to smaller molecules. Thus, 
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fluorescence polarization assay can be used to get a direct readout of the tracer binding to 
proteins, nucleic acids and biopolymers. The degree of polarization is calculated from the 
measurements of fluorescence intensities parallel (Fll) and perpendicular (F⊥) to the plane 
of the excitation polarized light, and is expressed in terms of fluorescence polarization (P) 
(Fig. 3.8).  
 
! 
P =
F || - F"
F || + F"
  (Eq. 1) 
 
We monitored the polarization of light emitted after the addition of 1 μM BODIPY FL 
GTPγS (excitation/emission maxima ~503/512 nm; Invitrogen) to a sample containing 2 
μM RhoA·GDP in 20 mM HEPES pH 8.0, 150 mM NaCl, 10 % glycerol, 10 mM MgCl2, 
1 mM DTT, ± (30 μM AlCl3, 10 mM NaF).  Samples were excited with plane- polarized 
light using a BMG LABTECH PHERAstar with 485/520 FP Module. 
 
Millipolarization (mP) of the emitted light was plotted versus time to obtain a one-phase 
exponential association curve describing RhoA nucleotide exchange.  The reaction was 
supplemented with various p63RhoGEF, Trio or Duet constructs to assay their GEF 
activity.  These reactions were further supplemented with Gαi/q in activation assays, as 
indicated.  In each individual experiment, each curve was measured in triplicate, and was 
fit to the three exponential association curves simultaneously with non-linear regression 
in GraphPad Prism.  The signal from the fluorophore alone is first subtracted from each 
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curve.  Ymax and the lag time were treated as a shared variable for all samples in the same 
plate, unless indicated.  
! 
Y = Ymax" 1 - exp -K" X + T0( )( )( )  (Eq. 2) 
where Y is the total fluorescence measured that starts at Y0 (at T0) and ascends to 
Y0+Ymax with a rate constant, K.  Fig. 3.9 shows an example of data obtained by 
fluorescence polarization assay of RhoA nucleotide exchange. 
 
 
 
Figure 3.8: Principle of fluorescence polarization assays. The fluorescent tracer 
molecules that are in line with the linearly polarized light are selectively excited. For the 
tracers attached to small rapidly rotating molecules, the fluorescence polarization is low. 
However, binding of the low molecular weight tracer to a large slowly rotating molecule 
results in high fluorescence polarization.  
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Figure 3.9: FP assay measuring RhoA nucleotide exchange. p63RhoGEF catalyzed 
GEF Activity was monitored by the increase in fluorescence millipolarization (mP) of 
BODIPY FL GTPγS as it bound to RhoA in the presence of 200 nM p63-149-338, p63-
149-477 or p63-149-502 constructs.  
 
Purification of the Gαi/q-(p63-149-502)-RhoA ternary complex  
 
Gαi/q was mixed with a 1.25 molar excess of pure p63RhoGEF-149-502 in the presence 
of 20 μM AlCl3 and 10 mM NaF and incubated on ice for 30 min.  Gαi/q-(p63-149-502) 
complexes thus formed were buffer exchanged with a 2 ml spin column (ZebaTM) to 
remove excess GDP.  RhoA was incubated with 10 mM EDTA on ice for 30 min and 
buffer exchanged with a 0.5 ml spin column to form GDP-free RhoA.  The Gαi/q-
(p63-149-502) complex was incubated with 1.5 molar excess of GDP-free RhoA on ice 
for 15 min and then resolved on two tandem Superdex 200 10/300 gel-filtration columns 
pre-equilibrated with 20 mM HEPES pH 8.0, 50 mM NaCl, 1 mM DTT, 1 μM EDTA, 
20 μM AlCl3 and 10 mM NaF (Fig. 3.12).  Fractions (0.3 ml) containing the 
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Gαi/q-(p63-149-502)-RhoA complex were pooled and concentrated to ~3.5 mg/ml using a 
Centricon YM-50.  Complex formation was not stable in the presence of GDP.  Similar 
complexes were also isolated using p63- 149-492. 
 
Crystallization of the Gα i/q-(p63-149-502)-RhoA complex 
 
Crystals were grown at 4°C by hanging-drop vapor-diffusion.  The ternary complex was 
mixed 1:1 with the well solution containing 0.3 - 1.2 M KCl, 14-17% PEG 3350 and 100 
mM HEPES (pH 6.5-7.5). Crystals typically grew within 2 days as extremely thin and 
long plates with dimensions of up to over 1 mm in length (Fig. 3.13).  Macroseeding, 
dehydration and glutaraldehyde crosslinking did not improve the quality of crystals. 
Microseeding enabled growth of comparatively thicker crystals. Diffraction data was 
analyzed and structure determined from a crystal grown in a microseeded drop 
equilibrated over 100 mM HEPES pH 6.5, 400 mM KCl and 14.5% PEG 3350. The 
crystal was harvested in cryoprotectant solution containing 20 mM HEPES pH 8.0, 
100 mM HEPES pH 7, 20% PEG 3350, 1.2 M KCl, 1 mM DTT, 50 mM NaCl, 1 µM 
EDTA, 20 µM AlCl3, 10 mM NaF and 20% MPD.  Crystals could also be grown using 
the p63-149-492 ternary complex.  
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Data Collection and Crystal Structure Determination  
 
Crystals of Gαi/q-(p63-149-502)-RhoA complex were screened at beam lines 23-ID-B 
and 23-ID-D at GM/CA-CAT, Only one crystal diffracted well enough to be indexed and 
revealed the space group to be P1 with pseudo C2 symmetry, with cell dimensions a=69 
b=69 and c= 85 Å,  α=85, β=81 and γ=89˚.  The low symmetry and radiation sensitivity 
of the crystals greatly hindered redundancy.  The Matthews coefficient (2.9) and a self-
rotation function were consistent with two complexes per unit cell. Two data sets were 
ultimately collected from a crystal diffracted anisotropically to beyond 3.5 Å spacings at 
LS-CAT beam line 21-ID-D (Table 3.2).  Data were processed and reduced using the 
HKL2000 package.  The structure was solved by molecular replacement with the 
program PHASER (Storoni, McCoy et al. 2004) using the structures of Gαi/q (Lodowski, 
Barnhill et al. 2005) and the Dbs-RhoA complex (Rossman, Worthylake et al. 2002) as 
search models, although the PH domain of Dbs was removed.  The resulting electron 
density maps were readily interpretable with only the β1-β2 and β3-β4 loops of the 
p63RhoGEF PH domain completely disordered (Fig. 3.14, Table 3.1).  The low 
redundancy of the data (2.5) is offset by the fact that there are two complexes per 
asymmetric unit, and thus tight NCS restraints and two-fold density averaging and 
solvent flattening could be used in the initial stages of model building and refinement 
using O (Jones, Zou et al. 1991) and REFMAC5 (Murshudov, Vagin et al. 1997; Winn, 
Isupov et al. 2001), respectively.  Later in the refinement, the “insertion helix” of RhoA 
and the N-terminus and adjacent α5-α6 loop of the p63RhoGEF DH domain were 
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determined to exist in distinct conformations in the two complexes of the asymmetric unit 
due to differences in local crystal contacts, and were therefore not two-fold restrained.  
After convergence of the structure, the use of Rfree was abandoned and all reflections 
were used for the final rounds of model building.  Both coordinates and diffraction data 
are deposited with the Protein Data Bank with PDB accession code 2RGN. 
 
Pull down assay of Gαq Mutants 
 
Mutations in Gαq were generated in mouse Gαq cDNA in pCMV5 and the mutants were 
expressed in HEK293 cells as described before (Tesmer, Kawano et al. 2005).  The cells 
were lysed with 1 ml of lysis byffer (20 mM Tris pH 8.0, 150 mM NaCl, 5 mM MgCl2, 
10 µM GDP, 0.5% Triton X-100 and protease inhibitors) and incubated on ice for 
20 min. The samples were centrifuged at 15,000g for 20 min at 4 °C and the resulting 
supernatants were collected.   The samples were subjected to trypsin protection assay to 
test the integrity of mutants. 10 µl of cell lysate was treated with 100 ng of trypsin either 
in the presence or absence of AlF4- (30 µM AlCl3 and 10 mM NaF) for 40 min at 30°C. 
Gαq was detected by Western analysis as described (Lodowski, Barnhill et al. 2005). 
 
p63-149-502 was biotinylated by incubating 80 µg of the protein with equimolar amounts 
of biotinamidohexanoyl-6-amino-hexanoic acid N-hydroxy-succinimide ester (Sigma) on 
ice for 1 hr. The conjugate was then filtered through 0.5ml ZebaTM desalt spin column. 
100 µl of the Gαq (WT or the mutant) cell lysates were incubated with 850 ng of 
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biotinylated p63-149-502 and streptavidin beads (Invitrogen) either in the presence or 
absence of AlF4- for 3 hr at 4°C. The beads were washed three times with 500 µl of the 
lysis buffer either with or without AlF4-. The beads were treated with 5 µl of 4X SDS-
PAGE loading buffer and Gαq was detected by Western analysis using the anti-Gq rabbit 
polyclonal antibody (C-19, Santa. Cruz Biotechnology) (Fig. 3.18).  
 
RESULTS & DISCUSSION 
 
Biochemical studies of p63RhoGEF constructs 
 
To define the elements of p63RhoGEF required for Gαi/q activation in vitro, we first 
expressed p63-149-477 and p63-149-580 (Fig. 3.5). In a direct binding assay, AF 532 
labeled p63-149-580 could bind AlF4- activated Gαi/q with a binding affinity (Kd) of 
43±4 nM, while AF 532 labeled p63-149-477 (DH/PH) had no measurable affinity for 
AlF4- activated Gαi/q (Fig. 3.10). This suggested that a high-affinity binding site for Gαi/q 
is present to the C-terminus of the PH domain of p63RhoGEF. In order to precisely 
identify the minimal fragment in p63RhoGEF required for Gαq binding, we tested the 72 
constructs of p63RhoGEF (spanning residues 295 through 580) in a competition-binding 
assay using FCPIA. The 72 constructs were tested for their ability to compete with p63-
149-580 for binding Gαi/q. 1.2 μM of each purified MBP-p63RhoGEF fragment produced 
by the high-throughput (HTP) core at the University of Michigan was used to compete 
with the binding of 100 nM Alexa Fluor 532-labeled p63-149-580 to 5 nM biotinylated 
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Gαi/q·Mg2+·GDP·AlF4- in a FCPIA assay (Fig. 3.10). MBP and unlabeled p63-149-580 
were used as negative (0% inhibition) and positive (100% 
inhibition) controls, respectively. p63-295-502 was identified as the minimal fragment 
required for full inhibition of Gαi/q-(p63-149-580) binding. In a direct binding assay, 
AF-532 labeled p63-149-502 bound AlF4- activated Gαi/q with a Kd of 36±3 nM, similar 
to that of p63-149-580 (Fig. 3.10). 
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Figure 3.10: Identification of the minimal Gαq-binding fragment of p63RhoGEF.  
(A) Equilibrium binding of p63RhoGEF fragments to Gαi/q measured by FCPIA. 
Dissociation constants (Kd’s) were determined by an equilibrium-binding FCPIA using 
various concentrations of AF 532–labeled p63RhoGEF fragments. In this experiment, Kd 
was 43 ± 4 and 36 ± 3 nM for p63-149-580 and p63-149-502, respectively. No binding 
was observed for p63-149-477. Binding was monitored by the median fluorescence 
intensity (MFI) and was corrected for nonspecific binding (MFI in the absence of AlF4–). 
(B) Competition of Gαi/q-(p63-149-580) binding with p63RhoGEF constructs. 1.2 μM of 
each purified MBP-p63RhoGEF construct was made to compete with the binding of 
p63-149-580 to AlF4- activated Gαi/q. Shown are the mean percent inhibitions measured 
in duplicates with samples from two independent HTP purifications. p63-295-502 was 
the minimal fragment that showed full inhibition of Gαi/q- (p63-149-580) binding (Lutz, 
Shankaranarayanan et al. 2007). 
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We next measured the GEF activity of p63RhoGEF constructs (p63-149-338 (DH), 
p63-149-477 (DH/PH) and p63-149-502) on RhoA at 200, 400, 600 and 800 nM GEF 
concentrations using the fluorescence polarization assay. Both p63-149-477 (DH/PH) and 
p63-149-502 possessed only weak GEF activity and their nucleotide exchange rate on 
RhoA (fold activation over RhoA alone) is less than 1/20th the rate of the isolated DH 
domain of the p63RhoGEF (p63-149-338) (Fig. 3.11A and Table 3.1). Thus it appears 
that the p63RhoGEF constructs containing the PH domain (p63-149-477, p63-149-502, 
p63-149-580) are autoinhibited. We then tested if Gαq can stimulate the activity of 
p63RhoGEF constructs in our assay. The GEF activity of 200 nM p63-149-502 was 
measured in the presence of increasing concentrations of AlF4- activated Gαi/q. The low 
basal GEF activity of p63-149-502 could be activated by Gαi/q in a saturable manner to 
three to four fold (Fig. 3.11B). The curves are fit based on the assumption that the Gαi/q-
stimulated GEF activity is due to complex formation between Gαi/q and p63RhoGEF.  
Thus, the data was fit to a saturation binding with ligand depletion curve (equation 3) 
with the concentration of GEF (p63-149-502) fixed at 200 nM. This yielded a Kd = 70±13 
nM for the association of Gαi/q and p63-149-502.  
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 (Eq. 3) 
 
The activity of p63-149-502 was also tested in cell-based assays at Wielandʼs lab in 
University of Heidelberg, Germany. The p63-149-502 fragment could mediate GαqRC (a 
constitutively active mutant defective in GTP hydrolysis) and M3- muscarinic acetylcholine 
 91 
receptor induced activation of RhoA and serum response factor (SRF) as effective as wild 
type p63RhoGEF in human embryonic kidney (HEK293) cells (Lutz, Shankaranarayanan 
et al. 2007).  
 
Thus, the p63-149-502 fragment, identified by the high-throughput study as the minimal 
fragment of p63RhoGEF required for Gαq binding and activation, was shown to be active 
and responsive to Gαq stimulation, both in vitro and in intact cells. Our data also suggested 
that Gαq activates p63RhoGEF by releasing the auto-inhibition of the catalytic DH 
domain by the PH domain. To understand the molecular basis of Gαi/q stimulated 
p63RhoGEF activation, we attempted to crystallize both the active 
Gαi/q-(p63-149-502)-RhoA ternary complex, p63-149-477-(DH/PH)-RhoA complex and 
the inactive p63RhoGEF constructs alone. We only obtained crystals of the ternary 
complex that were optimized to get a 3.5 Å resolution structure of 
Gαi/q-p63RhoGEF-RhoA as described in the methods section. 
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Table 2: GEF exchange rates and Gα i/q binding constants for Trio family RhoGEFs 
 
Fragment specific activity (sec-1·nM RhoGEF-1)x106 * Kd (nM)† 
p63-149-580 0.26 ± 0.3 65 ± 7 
p63-149-502 0.14 ± 0.04 53 ± 36 
p63-149-492 0.13 ± 0.01 71 ± 14 
p63-149-477 0.38 ± 0.1 NB 
p63-149-338 8.5 ± 0.4 ND 
Trio-1894-2232 0.54 ± 0.2 100 ± 20 
Duet-219-558 0.31± 0.06 166 ± 58 
* Average of ≥ 3 experiments (except p63-149-492 and p63-149-338, n=2) in which the 
nucleotide exchange activity of increasing concentrations of GEF (typically 0-800 nM, in 
steps of 200 nM) was measured on 2 µM RhoA.  The plot of activity versus GEF 
concentration is linear, and the data were fit by non-linear regression.  Values represent 
the average slope of the lines ± standard deviations. † Average of 3 or more separate 
FCPIA experiments using 5 nM biotinylated, bead-bound Gαi/q.  Non-specific binding was 
taken as the MFI in the absence of AlF4-. ‡ NB = no binding§ ND = not determined 
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Figure 3.11: Gα i/q stimulates the GEF activity of p63RhoGEF. (A) Basal GEF 
Activity of p63RhoGEF constructs monitored as shown in figure 3.10. In this experiment, 
p63RhoGEF DH domain was 25 and 35 times more effective in activating 2 µM RhoA 
than p63-149-477 and p63-149-502 constructs, respectively. Fold activation was 
calculated by dividing the p63RhoGEF activated nucleotide exchange rate by the intrinsic 
exchange rate of RhoA. (B) Stimulation of p63-149-502 by Gαi/q. The GEF activity of 
200 nM p63-149-502 was measured as shown in figure 3.10, but with added amounts of 
Gαi/q. Gαi/q stimulated rates were normalized against GEF alone to calculate fold 
activation. The data was fit to saturation curve with ligand depletion, shown as an inset. 
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Figure 3.12: Purification of the Gαi/q-(p63-149-502)-RhoA complex.  (A) Elution 
profile of the ternary complex on two tandem S200 10/300 gel-filtration columns.  (B) 
Peak fractions analyzed by SDS-PAGE.  Proteins were visualized by Coomassie Blue 
stain.  'M' denotes protein standard marker and 'L' the reaction mix load. Although 
activation of Gαq depends on the presence of Mg2+, and the interaction of p63RhoGEF 
with RhoA on the absence of Mg2+, the ternary complex remained stable in the presence 
of 1 μM EDTA.  
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Fig. 3.13.  Crystals of the Gαi/q-(p63-149-502)-RhoA complex.  (A) Typical crystal 
clusters.  Individual crystals are flexible and have a slight left-handed helical twist of 
pitch ~ 1 mm.  (B) A single crystal from improved crystallization conditions.  This 
crystal measured 800x90x16 μm.  
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Table 3: Crystallization data and refinement statistics  
X-ray Source:  LS-CAT beam line 21 ID-D 
Wavelength (Å) 0.9993 
Dmin (Å) 3.5 
Space group P1 
Cell constants (Å, °) a=67.2, b=68.1, c=138 Å, a=80.9, b=114.9, g=87.1˚ 
Unique reflections 29,299 (2,976)* 
Average redundancy 2.4 (2.5) 
Rsym (%)† 8.7 (53.1) 
Completeness (%) 97.1 (98.1) 
<I>/<σI> 10.7 (1.7) 
Refinement resolution (Å) 20 – 3.5  
Total reflections used 27,625 (1,859)‡ 
Protein atoms 13,524 
Non-protein atoms 74 
RMSD bond lengths (Å) 0.010 
RMSD bond angles (°) 1.2 
Estimated coordinate error (Å) 0.43 
Ramachandran plot statistics:  
    Most favored region, disallowed 
(%) 85.6, 0.0 
Rwork§ 24.5 (35.8) 
Rfree|| 29.0 (38.1) 
Rfinal¶ 24.4 (35.9) 
* Numbers in parentheses correspond to the highest resolution shell of data (3.62 – 3.50 Å). 
† Rsym = ΣhklΣi |I(hkl)i - I(hkl)|/ Σhkl I(hkl)i, where I(hkl) is the mean intensity of i reflections 
after rejections. 
‡ Numbers in parentheses correspond to the highest resolution shell of data (3.59 – 3.50 Å) 
§ Rwork = Σhkl||Fobs(hkl)| -|Fcalc(hkl)||/ Σhkl |Fobs(hkl)|; no I/σ cutoff was used during refinement. 
|| 5% of the truncated data set was excluded from refinement to calculate Rfree. 
¶ All reflections were used in the last several rounds of refinement. 
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Crystal structure of Gα i/q-(p63-149-502)-RhoA complex 
 
In the Gαq-(p63-149-502)-RhoA complex, Gαq interacts with both the DH and PH 
domains of p63RhoGEF, burying over 3600 Å2 of accessible surface area and no contacts 
are observed between Gαi/q and RhoA (Fig. 3.14). The C-terminus of the PH domain is a 
kinked α-helix (αCa and αCb helices, residues 471-485) and docks into the effector-
binding site of Gαi/q using residues that are conserved in the Trio subfamily of RhoGEFs 
and not in Dbs (Fig. 3.4). In addition, the α2-β4 and α3-β5 loops of Gαi/q make contacts 
with the 310 helix and the β2-β3 and β4-β5 loops of the p63RhoGEF PH domain.  
 
Gαi/q also contacts the DH domain with its α3-β5 and α4-β6 loops and the C-terminal 
α5 helix. The extreme C terminus of Gαi/q packs against a notch formed by a break in the 
α2 helix of the DH domain, where Tyr356 in Gαi/q forms extensive contacts with 
Gly208, Asn255 and Ile205 (Fig 3.16). This is the first observation of the C-terminus of a 
Gα involved in effector interaction and its possible that this interaction is specific to Gq 
subfamily. Thus, the C-terminus of Gαq can mediate interactions with both receptor and 
effectors (Janz and Farrens 2004; Oldham and Hamm 2008).  
 
The orientation of Gαi/q with respect to the expected membrane surface is similar as seen 
in the Gαi/q-GRK2-Gβγ complex and thus drastically different from the orientation of Gα 
in the inactive Gαβγ complex (Fig. 2.10 & 1.5). The interaction of the p63RhoGEF PH 
domain with the effector site of Gαi/q is very similar to the Gαi/q-GRK2 interaction (Fig. 
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3.15). In both cases, a long helix (αCa in p63RhoGEF and α5 in GRK2) docks right 
between the α2 (switch II) and α3 helices of Gαq. The overlapping portions in these 
helices exhibit a similar pattern of conserved hydrophobic residues that pack into the 
effector binding site, with the motif “471-ΦΦxΦLxx-477” (p63RhoGEF numbering, 
Φ=hydrophobic residue).  It is possible that all Gαq-regulated effector domains will use a 
similar structural motif to bind Gαq and Gα11. Also, the manner in which the 
p63RhoGEF PH domain contacts Gαi/q, is strikingly similar to the interaction of GRK2 
PH domain with Gβγ at the membrane surface (Fig. 3.15). The similarity in the 
interaction of these two PH domains with activated G proteins (Gαq and Gβγ) establishes 
a common theme in which PH domains interact with signaling partners at the cell 
membrane.  
 
 
Figure 3.14: Crystal structure of the Gα i/q-p63RhoGEF-RhoA complex. (A) Gαi/q   
interacts with both the DH and PH domains of p63RhoGEF but not with RhoA. N and C 
denote the most N- and C-terminal residues observed for each domain. Mg2+·GDP·AlF4– 
is shown as spheres. The three nucleotide-dependent conformational switches of Gαi/q  
(SwI, SwII, and SwIII) are red. The N-terminus of the chimeric Gαi/q extends toward the 
membrane surface, consistent with the N-terminal palmitoylation sites of Gαq  engaging 
the lipid bilayer while it is in complex with p63RhoGEF. (B) Side view of the 
Gαi/q-p63RhoGEF-RhoA complex. The PH domain is modeled in its expected orientation 
at the plasma membrane, which as a consequence juxtaposes the C-terminal 
geranylgeranylation site of RhoA with the lipid bilayer. 
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Figure 3.15: G protein-effector complexes at the membrane. (A) p63RhoGEF PH 
domain in complex with Gαi/q. The predicted membrane plane is based on the 
Inositol 1,4,5-trisphosphate (IP3) binding site on the phospholipase C–δ1 PH domain 
(Ferguson, Lemmon et al. 1995). (B) GRK2 RH domain in complex with Gαi/q. Only the 
α5 and α6 helices of GRK2 RH domain are shown. Both GRK2 and p63RhoGEF stack a 
long α helix against the effector-binding site of Gαi/q. In both the p63RhoGEF and GRK2 
complexes, Gαi/q is held in an orientation in which its longest axis is roughly parallel and 
switch I is held relatively close to the predicted membrane surface (top). (C) GRK2 PH 
domain in complex with Gβγ. The GRK2 and p63RhoGEF PH domains engage their 
protein targets in a similar way, using a C-terminal helical extension and the loops at one 
edge of the β1-β4 sheet of the PH domain to form an extensive protein interaction site.  
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Mutational Analysis of Gα i/q –p63RhoGEF interface 
 
We performed site-directed mutagenesis of p63-149-502 to test the role of three regions 
of Gαi/q-p63RhoGEF interface: the interface of Gαi/q effector site with the PH domain 
extension, the interface of the Gαi/q α2-β4 and α3-β5 loops with the remainder of the 
PH domain, and the interface of the Gαi/q α3-β5 and α5 region with the DH domain 
(Fig. 3.16). Every mutant was tested for its intrinsic GEF activity and for its ability to 
bind and be activated by Gαi/q (Table 3.3).  Mutations of residues in the C-terminal 
extension of p63RhoGEF PH domain (F471E, A474D, L475A, P478G and I479D) 
completely inhibited Gαi/q binding and activation, consistent with another recent study 
(Rojas, Yohe et al. 2007). Mutations in DH and PH domains had a minimal effect in 
Gαi/q binding, but some had a severe effect in Gαi/q activation. For example, mutations 
R204A, R244A, R245A and W216F in the DH domain contacts and mutations E385A 
and Q386A in the PH domain contacts resulted in the loss of Gαi/q activation, with no 
effect on Gαi/q binding. Thus the in vitro activation of p63RhoGEF appears to require the 
interaction of Gαi/q with both DH and PH domains.  
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Figure 3.16 Gα i/q-p63RhoGEF interfaces. (A) Stereo-view of the interaction of the 
C-terminal PH domain extension with the effector site of Gαi/q. Residues from 
p63RhoGEF PH domain are colored violet, and those from Gαi/q cyan. 
p63RhoGEF-Phe471, Leu472, and Leu475 are highly conserved in Trio family PH 
domains (Fig 3.4) and pack into the hydrophobic effector-binding site of Gαi/q. This 
interface is required for the high affinity binding and in vitro activation by Gαi/q (Table 
3.3).  (B) Interaction of the DH and PH domain with α-β loops and C-terminus of Gαi/q. 
Tyr356 in the C-terminus of Gαi/q packs against the DH domain adjacent to p63RhoGEF 
residues, Asn255, Ile205 and Arg204. Asp321 in the α4-β6 loop of Gαi/q appears to form 
a salt bridge with Arg245 of p63RhoGEF. The α2-β5 loop of Gαi/q packs against an 
intramolecular salt bridge in p63RhoGEF between residues Arg244 and Glu385. This 
interface is important for Gαi/q activation in vitro (Table 3.2).  
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Table 4: Mutational Analysis of Gα i/q-p63RhoGEF interface.  
Protein variant Fold activation 
GEF* 
Gi/q activation† Ki (nM)‡ 
p63-149-502 (wild type) 1.4 3.4 29 ± 4 
PH domain extension    
F471E 1.3 1.0 NB§ 
A474D 1.2 1.0 NB 
L475A 1.2 1.0 NB 
P478G 1.3 1.1 NB 
I479D 1.2 1.1 NB 
Y481A 1.3 3.2 205 ± 52 
Q482A 1.2 2.6 157 ± 32 
PH domain contacts    
A351K 1.2 3.1 54 ± 1 
E385A 1.4 1.2 79 ± 33 
Q386A 1.2 1.5 41 ± 10 
S415G 1.2 3.6 125 ± 15 
DH domain contacts    
R204A 1.2 1.7 66 ± 11 
Q212A 1.3 3.2 65 ± 19 
W216F 1.4 1.7 76 ± 33 
Y220A 1.4 2.3 126 ± 67 
R244A 1.3 1.4 72 ± 24 
R245A 1.4 1.2 84 ± 19 
Number represents the average of at least three experiments. * The ratio of the rate of 400 
nM GEF-induced nucleotide exchange divided by the intrinsic rate of RhoA exchange 
activity. Standard deviations were <8%.  
† Fold activation of 400 nM p63RhoGEF mediated by the addition of 800 nM Gαi/q. 
Standard deviations were ≤ 30%.  
‡ Average of 2 or more competition experiments in which the binding of 100 nM AF 532 
labeled p63-149-502 to bead-bound AlF4--activated Gαi/q was measured using FPCIA. 
Each protein concentration point (typically ranging from 0 to 1.8 µM) was measured in 
duplicate in each curve. A Kd of 50 nM for fluor-labeled p63-149-502 was used to 
convert median inhibitory values to Ki ± SD. 
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Figure 3.17: Identification of residues that define the specificity of Gαq interaction 
with p63RhoGEF. (A) Gαi/q in complex with p63RhoGEF. Side chains of interfacial 
residues in Gαq that were targeted for site-directed mutagenesis studies are shown as ball 
and stick models. (B) Sequence alignment of Gαq family members with Gαi1 Gαs and 
Gα13. The sequences are that of Switch II and Switch III are colored red. Gαq residues 
targeted for site-directed mutagenesis are highlighted in green. The sequences are those 
of rat Gαi1 GI:121020, bovine Gαt GI: 121031, bovine Gαs GI: 121000, mouse Gαq GI: 
84662745 and mouse Gα13 GI: 120984, mouse Gα11 GI: 6754004,  mouse Gα14 GI: 
160298199 and human Gα16 GI: 182891. Cylinders represent α-helices and arrows β-
strands. 
B 
A 
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Figure 3.18: Mutational analysis of Gαq residues involved in p63RhoGEF binding. 
Pull-down assays were performed by incubating the lysates of HEK293 cells expressing 
Gαq mutants with biotinylated p63RhoGEF (p63-149-502) or biotinylated RGS4 
immobilized on streptavidin beads either in the presence or absence of AlF4-. Bound Gαq 
was detected using a Gαq-specific antibody. All Gαq mutants expressed at similar level as 
WT Gαq (bottom panel).      
 
Of the mutants tested, the Gαq A253K and T257E mutants, designed to disrupt contacts 
with the PH domain extension, were mostly defective in binding p63RhoGEF (Fig. 3.18). 
The Gαq Y261N and W263D mutants, designed to disrupt interactions with the PH 
domain proper were less effective in binding p63RhoGEF compared to WT Gαq. The 
Gαq D321A mutant designed to disrupt the salt-bridge with p63RhoGEF-Arg245 appears 
to bind as well as the WT Gαq. Thus, A253, T257, Y261 and W263 are residues that are 
conserved in Gαq family members and dictate the specificity of p63RhoGEF interaction 
(Fig 3.17).  
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Figure 3.19: Role of the C-terminus of Gαq in p63RhoGEF interaction. (A) 
Activation-dependent binding of Gαi/q or mutant Y356A with fluor-labeled p63-159-502 
was monitored using FCPIA. In this experiment, a binding affinity of Kd = 70 ± 10 and 
62 ± 10 nM was observed for the binding of Gαi/q and Gαi/q  Y356A to p63-149-502, 
respectively. (B) Gαi/q Y356A does not activate p63-149-502 in FP assay. GEF activity 
of 200 nM p63-149-502 was measured in the presence of increasing amounts of Gαi/q 
Y356A. 
 
The interaction of the C-terminus of Gαq with the DH domain of p63RhoGEF 
represented a novel Gα-effector interface and the Gαq Y356A mutant was designed to 
test the importance of this residue in p63RhoGEF binding and activation (Fig. 3.19). Pull-
down assays with Gαq Y356A were not feasible due to its poor expression in HEK293 
cells.  The Y356A mutation was made in the Gαi/q chimera and expressed in High 5 
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insect cells. Gαi/q Y356A was purified as described for Gαi/q. Gαi/q Y356A was tested for 
its ability to bind and activate p63RhoGEF. Gαi/q Y356A bound fluor-labeled 
p63RhoGEF with essentially the same binding affinity as WT Gαi/q in FCPIA, but did not 
activate p63RhoGEF in the FP assay. Thus, our binding and activity assays performed 
with both p63RhoGEF and Gαq mutants suggest that Gαq interaction with both the DH 
and PH domains of p63RhoGEF is important for its activation.  
 
Activation of Trio and Duet by Gαq   
 
Many of the interacting residues observed in the Gαi/q-p63RhoGEF interface are also 
conserved in the Rho-specific C-terminal DH/PH tandem motifs of Trio and Kalirin/Duet 
(Fig. 3.4). We tested the hypothesis that the DH/PH domains of Trio and Duet are 
activated by Gαq. The constructs of Trio and Duet analogous to p63-149-502 (Trio-1894-
2232 and Duet-219-558) were cloned into the pMCSG9 vector and purified as described 
for p63-149-502. Both Trio-1894-2232 and Duet-219-558 bind Gαi/q with Kd of 
261 ± 61 nM and 160 ± 23 nM, respectively. Both Trio-1894-2232 and Duet-219-558 are 
also activated by Gαi/q in FP assay of RhoA nucleotide exchange (Fig. 3.20). The 
Wieland lab performed SRF activation assays to test Gαq activation of Trio and Duet 
were tested in HEK293 cells. Full-length Trio and Duet enhanced GαqRC- as well as 
muscarinic M3-receptor (M3-R) and Histamine H1-receptor (H1-R) induced activation of 
SRF (Fig. 3.20). In a recent work, the constitutively active ortholog of Gαq was shown to 
activate a splice variant of Trio in C. elegans called UNC73 E (Williams, Lutz et al. 
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2007). 
 
Figure 3.20: Regulation of Trio and Duet by Gαq. (A) Equilibrium binding of Trio 
family RhoGEFs to Gαi/q measured by FCPIA. In this experiment, Kd = 39 ± 7, 160 ± 23 
and 261 ± 61 nM for fluor-labled p63-149-502, Duet-219-558 and Trio-1894-2232, 
respectively. (B) FP assay showing the activation of Duet-219-558 and Trio-1894-2232 
by Gαi/q. Fold activation by Gαi/q is plotted as fold increase over nucleotide exchange 
rate catalyzed by 200 nM GEF. (C) GαqRC- as well as M3-R and H1-R induced activation 
of SRF in HEK293 cells is enhanced by co-transfection with full-length p63RhoGEF, 
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Duet and Trio. Means ± S.E. (n=12) of firefly/renilla luciferase ratios are shown.  
 
Insights into mechanism of activation of p63RhoGEF  
 
We superimposed the DH/PH domains from our structure of p63-149-502 on the 
structure of related DH/PH domains of Dbs and N-terminal DH and PH domains of Trio 
(N-Trio) (Rossman, Worthylake et al. 2002; Worthylake, Rossman et al. 2004; 
Chhatriwala, Betts et al. 2007). The relative orientation of DH and PH domains in p63-
149-502 is different from what is observed in Dbs and N-Trio. The DH and PH domains 
of Dbs and N-trio interact through conserved residues at their interface and have similar 
conformations in both GTPase-bound and free states. The DH-PH interfacial residues of 
Dbs and N-Trio are conserved in p63RhoGEF (Fig. 3.4), but in the Gαi/q bound 
conformation (Gαi/q-p63RhoGEF-RhoA structure), the PH domain is rotated by ~50° 
around the α6 helix of DH domain relative to those of Dbs and N-Trio (Fig. 3.21). One 
way in which Gαi/q might activate p63RhoGEF is by rotating the otherwise inhibitory PH 
domain away from the RhoA binding site of the catalytic DH domain.  
 
While the PH domain appears to be inhibitory in p63RhoGEF, in both Dbs and N-Trio, 
the PH domain facilitates GEF activity by directly contacting the associated GTPases. 
Structures of Dbs in complex with Cdc42 or RhoA and N-Trio in complex with Rac1 
show direct contacts between the PH domain and the associated GTPase with conserved 
residues in its β1 (Dbs- Gln834) and β4 (Dbs-Y889) strand supported by a conserved 
histidine in the end of the α6 helix of DH domain. While the glutamine in β1 strand and 
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the tyrosine in β4 strand are conserved in p63RhoGEF, Duet and C-Trio, the critical 
histidine in α6 helix of DH domain is variant. Hence such an interaction between PH 
domain of GEF and GTPase is not likely to be present in the p63RhoGEF family 
members.  
 
Figure 3.21:  A unique DH/PH conformation in the Gα i/q-p63RhoGEF-RhoA 
complex. The DH/PH domains of p63RhoGEF are closely related to those of Dbs and 
N-Trio, yet their DH/PH domains adopt distinct conformations.  Compared to Dbs and 
N-Trio, the PH domain is away from the RhoA site by a ~50° rotation around the α6 
helix of DH domain. Gαi/q is shown as a sphere model.  
 
In both Dbs and N-Trio, the β3-β4 loop of the PH domain also make hydrogen bonds 
with the α3b helix of bound GTPase. When the PH domain of p63RhoGEF is modeled in 
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the Dbs-like conformation, it appears like the β3-β4 loop might interfere in RhoA 
binding. We tested if the deletion of this loop might increase the low basal GEF activity 
of p63RhoGEF. We deleted residues 397 through 402 in the p63-149-502 construct by 
site-directed mutagenesis (Δ 397-402) and tested its GEF activity and binding to Gαi/q.  
In FP assay, the deletion of the β3-β4 loop had minimal effects on the fold increase in 
nucleotide exchange rate over RhoA, suggesting that the β3-β4 loop has no effect on the 
nucleotide exchange rate of p63RhoGEF (Fig 3.22). 
 
We also identified residues in the α6 helix of DH domain and the αN-βN region of 
p63RhoGEF that are conserved in the p63RhoGEF family, but not in Dbs or N-Trio. We 
hypothesized that these residues might play a role in maintaining the inhibited basal state 
of p63RhoGEF. We mutated these residues in the p63-149-502 construct to the 
corresponding residues in Dbs (P330L, M336S, G340I and R341A) and tested its GEF 
activity and binding to Gαi/q. The P330L mutant binds Gαi/q with a similar binding 
affinity as p63-149-502, but was severely hampered in the activation of GEF activity by 
Gαi/q. Pro330 causes a kink in the α6 helix of DH domain that appears to be important 
for the GEF activity. The M336S mutation had little effect on p63RhoGEF activation by 
Gαi/q. Both P330L and M336S bind Gαi/q with similar binding affinity as p63-149-502 
(Fig. 3.22 & Table 3.4). 
 
For the G340I and R341A mutants of p63-149-502, we measured their initial rates of 
nucleotide exchange by measuring its GEF activity at various GEF concentrations and 
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also in the presence of excess Gαi/q. p63-149-502 protein has a nucleotide exchange rate 
of 0.72 µM-1, which is enhanced to 18.4 µM-1 in the presence of saturating concentrations 
of Gαi/q (~25 fold over basal GEF rate). Both G340I and the R341A mutants had higher 
rates of nucleotide exchange on RhoA (9.5 µM-1and 4 µM-1, respectively). This suggests 
that both G340 and R341 residues contribute to low basal activity of p63RhoGEF. We 
tested if the increased rate of nucleotide exchange is due to increased binding affinity to 
RhoA. R341A clearly has increased binding affinity to nucleotide-free RhoA. When the 
PH domain of p63RhoGEF is modeled as in Dbs, R341 appears to repel R68 in the 
switch II of RhoA. We mutated the R341 residue to glutamic acid to test if the binding 
affinity to RhoA increases by favoring the interaction with R68 of RhoA. Indeed, the 
R341E mutant has a lower Kd compared to R341A mutant and p63-149-502. Thus R341 
inhibits the basal GEF activity of p63RhoGEF by inhibiting RhoA binding. Because the 
G340I mutant has a similar binding affinity to nucleotide-free RhoA as p63-149-502, it 
inhibits the basal GEF rate by a different mechanism (Fig. 3.23).  
 
The rates of nucleotide exchange for G340I and R341A mutants in the presence of Gαi/q 
were measured as 279.2 µM-1 and 74.3 µM-1 respectively. The G340I and the R341A 
mutant are activated to ~29.5 fold and ~18.4 fold over their basal GEF rates by Gαi/q, 
respectively (Fig. 3.22). Interestingly, the G340I mutant has a much lower binding 
affinity (~10 fold) to Gαi/q compared to that of p63-149-502.  
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Figure 3.22: Mutational analysis of residues in the α6 helix/αN-βN region of 
p63RhoGEF. (A) The basal GEF activity of 400 nM p63-149-502 (or its mutants) and its 
activation by 800 nM Gαi/q was measured using the FP assay. Data is plotted as fold 
activation over the intrinsic rate of 2 µM RhoA. (B) The GEF activity of p63-149-338 
(10, 20 and 40 nM), p63-149-502 (100, 200 and 400 nM), p63-149-502 (25, 50 and 
100 nM) in the presence of 800 nM Gαi/q, p63-149-502 G340I (100, 200 and 400 nM), 
p63-149-502 G340I  (2.5, 5 and 10 nM) in the presence of 800 nM Gαi/q, p63-149-502 
R341A (100, 200 and 400 nM), p63-149-502 R341A (10, 20 and 40 nM) in the presence 
of 800 nM Gαi/q were measured. In each case, fold activation over the intrinsic rate of 
RhoA was plotted against the GEF concentrations and the data was plotted to a straight 
line and the slope (fold over RhoA/ µM of GEF) is shown here.  
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Figure 3.23: RhoA binding properties of R341 and G340 mutants of p63RhoGEF. 
(A) Various concentrations of p63-149-502, G340I, R341A or R341E mutants were used 
to compete with the binding of 200 nM AF-532 labeled R341A mutant binding to bead-
bound RhoA in the presence of 10 mM EDTA. The Kd value calculated from direct 
binding of AF-532 labeled R341A mutant binding to bead-bound RhoA was used to 
convert median inhibitory concentration values to Ki values. (B) Binding of RhoA to 
Gαi/q-p63RhoGEF (or mutants) complex. Shown are the apparent Kd values for the 
binding of 5 nM bead-bound AlF4- activated Gαi/q to varying concentrations of AF 532 
labeled RhoA in the presence of 400 nM unlabeled p63-149-502. 
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Table 5: Gα i/q binding properties of p63RhoGEF mutants*. 
                                         Ki Values (nM) 
  Average SD 
p63-149-502 29.1 7.9 
P330L 30.5 2.2 
M336S 51.1 14.6 
G340I 459.7 340.3 
R341A 50.8 22.5 
R341E 85 25.9 
D (397-402) 31.5 3.3 
1A 170.3 37.3 
2A 278.6 8.5 
3A 135.1 27 
4A 36.7 3.4 
5A 233.03 19.4 
6A 222.03 18.6 
7A 111.2 7.9 
*Varying concentrations of p63-149-502 or its mutants were used to inhibit the binding of 
100 nM AF 532 labeled p63-149-502 with bead-bound, AlF4- activated Gαi/q. The Kd 
value calculated from direct binding of AF-532 labeled p63-149-502 with bead-bound, 
AlF4- activated Gαi/q was used to convert IC50 values to Ki.  
 
In order to understand if the relative orientation of DH and PH domains in p63RhoGEF 
contributes to its low basal GEF activity, we made a series of alanine insertion mutants 
(1A, 2A…7A) after T338 in the α6 helix of p63-149-502 DH domain. Insertion of an 
alanine in an α-helix would introduce a 100° turn and a displacement of 1.5 Å to its C-
terminus and hence we expected to shift the relative orientation of DH and PH domains 
in p63-149-502. As expected, insertion of one or two alanines (1A or 2A) increases the 
basal GEF activity of p63-149-502 by ~3 fold, but lose enhancement of their basal GEF 
activity by Gαi/q (Fig. 3.22) All the other alanine insertion mutants have similar GEF 
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activity as p63-149-502 and also lose activation by Gαi/q. All alanine insertion mutants 
have decreased binding affinity to Gαi/q, except the 4A mutant. Taken together, the 
results suggest that the C-terminus of α6-helix of DH domain is critical in fixing the 
relative orientation of DH and PH domains that is important for binding and activation by 
Gαq.  
 
Implications of the Gα i/q –p63RhoGEF-RhoA structure 
 
The structure of the Gαi/q-p63RhoGEF-RhoA complex reveals the molecular details of 
three proteins caught in the action of relaying signals from heterotrimeric G proteins to 
RhoA. Our structure and the in vitro binding and activity assays show that Gαi/q activates 
p63RhoGEF by engaging both its DH and PH domains, thereby releasing its auto-
inhibited state. While precise structural details of the inactive state of p63RhoGEF is 
unclear, it is apparent that the residues in the C-terminus of DH domain contribute to the 
auto-inhibited state by mechanisms that include inhibition of RhoA binding and 
restricting the relative orientation of DH and PH domains. Additional factors such as Gαq 
mediated recruitment of p63RhoGEF to the plasma membrane and interaction of the PH 
domain with membrane bound phospholipids could also play a role in activation 
mechanism.  
 
The interaction of p63RhoGEF with Gαq effector-binding site is similar to Gαq-GRK2 
interface and the GAP binding site of Gαq is free to interact with a RGS protein like 
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RGS2 or RGS4. Thus both Gαi/q-GRK2 and Gαi/q-p63RhoGEF interfaces suggest the 
formation of a RGS-Gαq-effector complex is possible, similar to the RGS9-Gαt-PDEγ 
complex. In Chapter 4, we have detailed our kinetic studies that confirm the formation of 
such high order signaling complexes and the functional implications they have for Gαq 
signaling. 
 
We have shown that Gαq activates p63RhoGEF-related members, Trio and Duet. It was 
recently shown that UNC-73, the C. elegans ortholog of human Trio is activated by the 
constitutively active C. elegans ortholog of Gαq called EGL-30. Genetic studies in C. 
elegans confirm that the interaction of EGL-30 with both UNC-73 and EGL-8 (C. 
elegans ortholog of PLCβ) is critical to regulate levels of second messenger 
diacylglycerol (DAG), which controls neuronal activity related to locomotion, egg laying 
and growth of the animal (Williams, Lutz et al. 2007). Its possible that the Gαq-
p63RhoGEF pathway could be important in RhoA induced neuronal processes in humans 
such as neurite outgrowth and differentiation, axon pathfinding, and dendritic spine 
formation (Govek, Newey et al. 2005). 
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Chapter 4 
 
 
 
Regulation of Gαq Signaling by 
RGS proteins  
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BACKGROUND AND RESEARCH PLAN 
 
RGS2 and RGS4 belongs to the B/R4 subfamily of RGS proteins, which contains a 
membrane-targeting domain, N-terminus to the RGS box (Zheng, De Vries et al. 1999; 
Heximer, Lim et al. 2001; Kehrl and Sinnarajah 2002{Soundararajan, 2008 #162; 
Soundararajan, Willard et al. 2008). RGS2 and RGS4 are key regulators of Gαq signaling 
in the heart. In vivo studies in adult ventricular myocytes indicate that RGS2 is the only 
selective inhibitor of Gq/11 signaling in the heart (Hao, Michalek et al. 2006). In fact, both 
heterozygous and homozygous RGS2 knock out mice are hypertensive and RGS2 is 
shown to play an important role in the regulation of blood pressure and cardio-vascular 
development by inhibiting Gαq- stimulated cardiac hypertrophy (Rogers, Tamirisa et al. 
1999; Borchers, Biechele et al. 2003; Heximer, Knutsen et al. 2003; Lutz, Freichel-
Blomquist et al. 2005; Hercule, Tank et al. 2007).  
 
The rate of GTP hydrolysis by Gαq is slow (~ 0.8 min-1) in a steady state GTPase assay, 
in which Gq and M1 muscarinic receptors are reconstituted in lipid vescicles (Chidiac 
and Ross 1999); (Berstein, Blank et al. 1992). The receptor stimulated GTPase activity of 
Gq can be enhanced by RGS proteins to several hundred folds (Hepler 1999; Zhong and 
Neubig 2001). In spite of the high structural and sequence similarity of the RGS domains, 
RGS4 functions as a GAP for both Gαq and Gαi, while RGS2 is highly selective for Gαq 
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(Fig. 4.1) (Berman, Kozasa et al. 1996; Heximer, Cristillo et al. 1997). Studies in the 
Hepler lab have shown that RGS2 selectively binds Gαq and it is 10-fold more potent 
than RGS4 in vitro and 5-fold more potent than RGS4 in vivo as an inhibitor of Gq-
stimulated PLCβ1 activity (Heximer, Cristillo et al. 1997; Heximer, Srinivasa et al. 1999; 
Heximer 2004).   
 
The structural basis for the specificity of RGS2-Gαq interaction is unclear. Blumer et al 
showed that mutation of three amino acids (C106, N184 and E191) in the putative Gα 
binding surface of RGS2 increased its GAP activity towards a Gαi family member, Gαo 
(Heximer, Cristillo et al. 1997; Heximer, Srinivasa et al. 1999). The triple mutant 
however was similar to wild type RGS2 in inhibiting Gαq stimulated PLCβ1 activity. 
Recent studies show that the N-terminus of RGS2 selectively binds the third intracellular 
loop of Gq-coupled receptors like α1A-adrenergic receptor and M1 muscarinic 
acetylcholine receptor. Based on these results, one emerging model is that the Gαq 
selectivity of RGS2 is due to its ability to bind Gq-coupled receptors (Bernstein, 
Ramineni et al. 2004; Hague, Bernstein et al. 2005; Tikhonova, Boulegue et al. 2006). In 
order to structurally characterize the differential specificity of Gαq for RGS2 and RGS4, 
we pursued the crystallization of Gαq in complex with RGS2 or RGS4.   
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Figure 4.1: Comparison of Gα i-RGS4 structure with the Gαq-RGS2 docking model. 
The RGS domains of RGS2 and RGS4 that stabilizes the switch regions of Gα subunit 
share a high level of structural similarity. Yet, RGS2 is selective for Gαq and RGS4 can 
regulate both Gαi and Gαq signaling. RGS2 and RGS4 are shown in dark and light green, 
respectively. Gαi and Gαq are shown in pale blue and cyan, respectively. 
Mg2+·GDP·AlF4- is shown as ball and stick model.    
 
Crystal structures of Gαi/q-GRK2-Gβγ (Tesmer, Kawano et al. 2005) and 
Gαi/q-p63RhoGEF-RhoA complex (Lutz, Shankaranarayanan et al. 2007) demonstrated 
that GRK2 and p63RhoGEF both engage Gαq in a manner that appear to allow the 
binding of the RGS domain of either RGS4 (Tesmer, Berman et al. 1997) or RGS2 
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(Tesmer, Berman et al. 1997; Soundararajan, Willard et al. 2008) to Gαq without steric 
overlap (Fig. 4.2). Models of these RGS-Gαi/q-effector complexes thus resemble the 
structure of the PDEγ-Gαi/t-RGS9 complex (Fig. 4.2).  The positions of the modeled RGS 
box domains in these complexes are also consistent with the predicted orientation of 
these complexes at the cell surface, in that the expected membrane binding elements of 
the RGS proteins (such as its N-terminus and α4-α5 loop) are juxtaposed with the 
phospholipid bilayers (Popov, Krishna et al. 2000; Heximer, Lim et al. 2001).   
 
The functional significance of RGS-Gα-effector complex is well understood in the 
vertebrate phototransduction cascade. It was observed that the GAP activity of RGS9 for 
the visual G protein transducin (Gαt) is enhanced by the γ subunit of its effector PDEγ 
(He, Cowan et al. 1998). Although PDEγ has no GAP activity on its own, it enhanced the 
GAP activity of RGS9 by up to ~3 fold. Biophysical studies and the crystal structure of 
RGS9-Gαt/i1-PDEγ complex demonstrated that GAPs and effectors can simultaneously 
engage Gα subunit and that the GAP activity of RGS9 on transducin is allosterically 
modulated by effector (PDEγ) binding (Skiba, Yang et al. 1999; Slep, Kercher et al. 
2001). It has been proposed that PDEγ regulated GAP activity of RGS9 prevents a “short-
circuit” of the phototransduction cascade via premature hydrolysis of Gαt·GTP before 
effectors can functionally interact with the G protein (Nekrasova, Berman et al. 1997). 
Also, PDEγ was shown to inhibit the GAP activity of RGS4, GAIP and RGS16, likely 
through a negative allosteric mechanism.  
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It was not known if ternary complexes of Gαq, effectors and RGS4/RGS2 exist and 
effectors allosterically modulate the GAP activity of Gαq by RGS proteins. We have 
performed in vitro experiments such as size exclusion chromatography; FCPIA and GAP 
assays to confirm the formation of RGS-Gαq-effector complexes and to better understand 
the roles of RGS proteins in modulating the interactions of Gαq with GRK2 and 
p63RhoGEF. 
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Figure 4.2: Models of Gαq effector complexes with RGS proteins.  To generate these 
models, the structure of Gαi/q in the Gαi/q-GRK2-Gβγ complex (PDB ID: 2bcj) and Gαi/q 
in the Gαi/q-p63RhoGEF-RhoA complex (PDB ID: 2rgn) were superimposed on Gαi in 
the Gαi-RGS4 structure (PDB ID: 1agr), which positioned RGS4 at the RGS-binding site 
on the surface of Gαi/q.  There was no obvious steric overlap between the docked-RGS4 
and either GRK2 or p63RhoGEF except for the protruding β6-β7 loop of the 
p63RhoGEF PH domain, which comes into contact with the α3 helix of the RGS box 
domain.  However, this loop can likely adopt many conformations.  Both the Gαq-GRK2-
Gβγ and Gαq-p63RhoGEF peripheral membrane complexes contain markers, including 
the prenylation sites of Gγ and RhoA, that help define how the complexes could be 
oriented with respect to the cell surface.  The expected membrane surface is parallel to 
the top of each panel.  (A) Model of RGS4 bound to the Gαi/q-GRK2 complex.  The PH 
domain of GRK2 was omitted for clarity.  Gα is colored cyan with orange β-strands, and 
the three switch regions (SwI, SwII and SwIII) are colored red.  Mg2+·GDP· AlF4- in the 
active site of Gαi/q is shown as a sphere model.  Carbons are colored rose, nitrogens blue, 
oxygens red, Mg2+ black, Al3+ sand, and F- light blue.  The kinase and RH domains of 
GRK2 are colored yellow and purple, respectively, and RGS4 is green.  N and C denote 
the observed amino and carboxyl termini of the proteins.  (B) Model of RGS4 bound to 
the Gαi/q-p63RhoGEF complex.  The DH and PH domains of p63RhoGEF are colored 
yellow and purple, respectively.  (C) Structure of the RGS9-Gαt/i1-PDEγ complex (PDB 
ID: 1fqj) with the Gα subunit in the same orientation as Gαi/q in panels A and B.  PDEγ 
and RGS9 are colored purple and green, respectively. 
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MATERIALS AND METHODS 
 
Purification of RGS2/RGS4 
 
Human RGS2 (1-211), RGS2 (72-211) (ΔN-RGS2) and RGS2 (1-71) was cloned into 
pMALc2H10T vector using the BamHI and SalI restriction sites and expressed as a MBP 
fusion protein. RGS2 expression vectors were transfected into Rosetta (DE3) pLys cells 
and grown in Luria-Bertani media supplemented with 50 µg/mL carbenicillin at 37 °C 
until it reaches an OD600 of 0.8. Expression of RGS2 was induced by addition of 
100 µg/mL of isopropylthiogalactopyranoside at 20 °C. The cells were harvested after 
20 hr by centrifugation at 7000 rpm for 10 min and frozen in liquid nitrogen.  The cell 
pellets were resuspended in lysis buffer (20 mM HEPES pH 8.0, 500 mM NaCl, 10 mM 
β-ME) plus 1 µM leupeptin, 1 mM lima bean trypsin inhibitor and 0.1 mM 
phenylmethylsulphonyl fluoride. The cells were lysed by an Avestin Homogenizer and 
ultracentrifuged at 40000 rpm for 1 hr using a Beckman Type Ti 45 rotor. The 
supernatant was loaded on a Ni-NTA column pre-equilibrated with lysis buffer. The 
column was washed with 10 column volumes of lysis buffer followed by 10 column 
volumes of lysis buffer plus 20 mM imidazole pH 8.0. MBP-RGS2 was eluted with lysis 
buffer plus 150 mM imidazole pH 8.0. MBP-RGS2 was treated with 2% TEV protease 
and dialyzed against the lysis buffer overnight. The dialysate was passed over the 
Ni-NTA column equilibrated with lysis buffer to remove His-tagged MBP. The flow 
through containing RGS2 was concentrated in a 30 kDa Centriprep (Millipore) and 
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gel-filtered using two tandem Superdex S200 columns equilibrated with 20 mM HEPES 
pH 8.0, 500 mM NaCl and 5 mM DTT. The yield of pure RGS2 is ~5 mgs and that of 
ΔN-RGS2 is ~3 mgs per liter of E. coli culture. MBP-R2 (1-71) is not TEV-cleaved and 
we obtain ~1.5 mgs of the protein per liter of E. coli culture. Rat RGS4 was purified as 
described before (Srinivasa, Watson et al. 1998). A construct expressing a fragment of 
RGS4 analogous to ΔN-RGS2 (RGS4- spanning amino acid residues 51-205) was created 
in pMALc2H10T vector using the EcoRI and Hind III restriction sites. The overexpressed 
protein was purified as described for RGS2 except using 100 mM instead of 500 mM 
NaCl.  
 
 
 
Figure 4.3: Primary structure and purification of RGS2/RGS4 A) Domain 
architecture of RGS4 and RGS2. B) SDS-PAGE analysis of the peak fractions from gel 
filtration chromatography of RGS2. RGS4 was also purified to similar level of purity. 
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Purification of Gα i/q-RGS2/RGS4 complexes 
 
We attempted to form a stable complex of Gαi/q with RGS4 or RGS2 in an activation 
dependent manner. We first tried to form Gαi/q-RGS4 complex by mixing Gαi/qβγs 
heterotrimer with molar excess of RGS4 in an activation buffer containing 20 mM 
HEPES (pH 8.0), 100 mM NaCl, 5 mM MgCl2, 50 µM GDP, 2 mM DTT, 10 mM NaF 
and 30 µM AlCl3 and incubating the reaction on ice for at least 15 min. The reaction mix 
was loaded on a two tandem Superdex S200 columns. Gαi/q complexes with RGS2 or 
ΔN-RGS2 were formed with a similar protocol, except with 500 mM NaCl and 5 mM 
DTT in the activation buffer. Gαi/q-RGS complexes were also formed using pure Gαi/q 
instead of Gαi/qβγs (Fig. 4.4). 
 
Gel-filtration analysis of Gα i/q interaction with GRK2 and RGS4/RGS2 
 
To investigate whether GRK2 and RGS4/RGS2 can bind at the same time to activated 
Gαq, the Gαi/q-GRK2 complex (900 µg), purified as described in Chapter 2, was mixed 
with a 1.5 – 8 molar excess of RGS4 (535 µg) in 200 µl activation buffer and incubated 
at 30°C for 15 min.  The reaction mixture was injected onto gel-filtration columns 
pre-equilibrated in activation buffer. The peak fractions were analyzed by SDS-PAGE 
(Fig. 4.6). 
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We next investigated if the Gαi/q-GRK2-Gβγwt complex associated with RGS4/RGS2. 
Gαi/q-GRK2-Gβγwt complex was formed in detergent micelles (10mM CHAPS) as 
described before and the final reaction mix was supplemented with two molar excess of 
RGS2 and incubated on ice for 1 hr before gel-filtration. 
 
We tested if Gαi/q in a GTPγS bound conformation would form a complex with GRK2 
and RGS4/RGS2. Since the rate of GDP dissociation by Gαq is very slow, we first 
isolated a complex of Gαi/q in complex in Ric8A, a non-receptor GEF that facilitates 
GDP dissociation by stabilizing the nucleotide free conformation of Gαq (Tall, Krumins 
et al. 2003; Tall and Gilman 2004). Purified GST-Ric8A was a gift from Dr. Greg Tall, 
UT Southwestern Medical Center, Dallas. Purified Gαi/q was incubated with TEV-
cleaved GST-Ric8A in 20 mM HEPES pH 8.0, 150 mM NaCl, 2 mM DTT and 10 mM 
EDTA and gel-filtered in the same buffer, except with 1 mM EDTA. Nucleotide free 
Gαi/q-Ric8A complex elutes as a single peak with an apparent molecular weight of 
107 kDa (Fig. 4.7). Gαi/q-Ric8A peak fractions were pooled, concentrated and incubated 
with equimolar amounts of GRK2 and two molar excess of RGS2/RGS4 in the presence 
of 500 mM NaCl, 100 µM GTPγS and 10 mM MgCl2 and gel-filtered in 20 mM HEPES 
pH 8.0, 500 mM NaCl, 10 mM MgCl2, 100 µM GTPγS and 1 mM EDTA (Fig. 4.7). 
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Gel-filtration analysis of Gα i/q interaction with p63RhoGEF and RGS4/RGS2 
 
Gαi/q and a 1.25 molar excess of p63RhoGEF and a 2 molar excess of RGS4/RGS2 were 
incubated on ice for 30 min in the presence of 20 µM AlCl3 and 10 mM NaF.  Total 
protein concentration was greater than 5 mg/mL.  RGS4-Gαi/q-p63RhoGEF complexes 
thus formed were gel filtered through a 2 ml desalting spin column (ZebaTM) to remove 
excess GDP.  RhoA was incubated with 10 mM EDTA on ice for 30 min and buffer 
exchanged with a 0.5 ml spin column to form GDP-free RhoA.  The 
RGS4-Gαi/q-p63RhoGEF complex was then incubated with 1.5 molar excess of GDP-
free RhoA on ice for 15 min and resolved on two tandem Superdex 200 10/300 gel-
filtration columns pre-equilibrated with 20 mM HEPES pH 8.0, 50 mM NaCl, 1 mM 
DTT, 1 µM EDTA, 20 µM AlCl3 and 10 mM NaF (Fig 4.8). 
 
Gαq GTPase Assay: 
 
In a Gα GTPase assay, the Gα protein is loaded with γ-P32 labeled GTP, residual 
nucleotides are removed and the hydrolysis of Gα-bound GTP is monitored over time.  
The rate of nucleotide exchange of GDP for GTP by Gαq is extremely slow that sufficient  
Gαq-GTP does not accumulate for GTPase assay. Dr. Elliot Ross lab showed that the rate 
of nucleotide exchange on Gαq can be accelerated in the presence of (NH4)2SO4 and the 
GαqR183C mutant that hydrolyzes bound GTP slowly (0.005min-1) responds to PLCβ 
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and RGS proteins (Chidiac, Markin et al. 1999). Since then, GαqR183C mutant has been 
routinely used to see the effect of effector/GAPs on rate of Gαq-GTP hydrolysis. 
 
Purification of Gαi/qR183C was performed as described for Gαi/q with the following 
modifications. The Ni-column eluate is substituted with 10% glycerol, dialyzed overnight 
against dialysis buffer (20 mM HEPES pH 8.0, 100 mM NaCl, 2 mM DTT, 1 mM 
MgCl2, 50 µM GDP and 10% Glycerol) and concentrated to ~8mg/ml. Gαi/qR183C was 
purified on a tandem S200 gel-filtration column pre-equilibrated with 20 mM HEPES 
pH 8.0, 200mM NaCl, 5 mM DTT, 5 mM MgCl2, 50 µM GDP and 5% Glycerol. Pure 
Gαi/qR183C was concentrated to ~3mg/ml and frozen as 5 µl aliquots in -80C freezer.  
 
γ-P32-GTP was added to 130 µl of GTP cocktail (50 mM HEPES (7.4), 1 mM EDTA, 
1 mM DTT, 0.9 mM MgSO4, 5.5 mM CHAPS, 0.1 mg/ml BSA, 6.25 µM GTP, 5% 
glycerol and 37.5 µM (NH4)2SO4) and a sample of it was counted in a liquid scintillation 
counter to calculate the standard (cpm/fmol). Gαi/qR183C (1-3 µM) was incubated with 
120 µl GTP cocktail for ~3 hr at 20°C. GTP bound Gαi/qR183C was purified from 
residual nucleotide at 4°C by desalting through 0.5 ml ZebaTM Desalt Spin Columns pre-
equilibrated with 50 mM HEPES (7.4), 1 mM EDTA, 1 mM DTT, 0.9 mM MgSO4, 
1 mM CHAPS, and 0.1 mg/ml BSA. Purified GTP-bound Gαi/qR183C was stored on ice 
and a sample of it was counted in a liquid scintillation counter to calculate the 
concentration of loaded Gαi/qR183C. 
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GTPase Assay was performed at 20°C in a assay buffer composed of 20mM HEPES 
(7.4), 80mM NaCl, 1mM EDTA, 1mM DTT, 0.9mM MgSO4, 1mM GTP, 0.2% Cholate 
and 0.01mg/ml BSA. GTPase Assay was initiated by addition of 30 µl of GTP-bound 
Gαi/qR183C to 270 µl of assay buffer in the presence or absence of GAP. At desired time 
points, the reaction was terminated by adding 50 µl of reaction mix to 750 µl of quench 
buffer (5% activated charcoal in 50 mM NaH2PO4, pH 2) on ice and radioactivity (γ-P32) 
in 300 µl of supernatants is counted in a liquid scintillation counter.  
 
RGS protein pull-down assays 
 
Mutations in Gαq were generated in mouse Gαq cDNA in pCMV5 and the mutants were 
expressed in HEK293 cells as previously described (Lodowski, Barnhill et al. 2005).  
RGS2/RGS4 was biotinylated by incubating with equimolar amounts of 
biotinamidohexanoyl-6-amino-hexanoic acid N-hydroxy-succinimide ester (Sigma) on 
ice for 1 hr and then filtering the sample through a 0.5 ml spin column (ZebaTM).  Gαq 
(WT or the indicated mutant) cell lysates (100 µl) were incubated with 1 µg of 
biotinylated RGS2/RGS4 and streptavidin beads (Invitrogen) for 3 hr at 4°C in the 
presence or absence of 30 µM AlCl3, 10 mM NaF.  The beads were then washed three 
times with 500 µl of the lysis buffer (± 30 µM AlCl3, 10 mM NaF as appropriate), and 
then treated with 5 µl of 4X SDS-PAGE loading buffer.  Gαq was detected by Western 
analysis. 
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RESULTS AND DISCUSSION 
 
Results of the gel-filtration analysis with Gαq and RGS proteins 
 
We attempted to form Gαi/q-RGS complexes by incubating Gαi/qβγs or pure Gαi/q with 
RGS4/RGS2 as described in the methods. In case of Gαi/qβγs, we obtained overlapping 
elution peaks of Gαi/qβγs and Gαi/q-RGS4 (Fig. 4.4). We were able to isolate a stable pure 
Gαi/q-RGS4/RGS2 complex when pure Gαi/q (βγs free) was reacted with 1.5 molar excess 
of RGS4/ RGS2 (Fig 4.4 & 4.5A).  
 
 
Figure 4.4: Gα i/q forms a complex with RGS4 in an activation dependent manner. 
Size exclusion chromatography of RGS4 alone (A), RGS4 and Gαi/qβγs in the absence of 
AlF4- (B), RGS4 and Gαi/qβγs in the presence of AlF4- (C) and RGS4 and Gαi/q in the 
presence of AlF4-(D). Similar results were obtained with RGS2. 
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Based on the crystal structure of Gαi-RGS4, the only interface of RGS2/RGS4 that is 
thought to contact Gαq is the RGS domain (Tesmer, Berman et al. 1997). To that extent, 
we were able to isolate a stable complex of Gαi/q and ΔN-RGS2 by size exclusion 
chromatography (Fig 4.5B). The peak fractions containing the Gαi/q-RGS complexes 
were pooled, concentrated to ~10 mg/mL and set to crystallization trials. So far, we have 
not been able to obtain crystals of Gαi/q in complex with RGS proteins. 
 
Figure 4.5: Purification of Gα i/q-RGS2/ΔN-RGS2 complex. Pure Gαi/q was incubated 
with 1.5 molar excess of RGS2 (A) or ΔN-RGS2 (B) in the presence of Mg2+, GDP and 
AlF4- for 15 min on ice and gel-filtered on a two tandem Superdex S200 columns. The 
elution profile of the gel-filtration run (top) and the peak fractions of the size exclusion 
run analyzed by SDS-PAGE (bottom) are shown. 'M' denotes the protein standard marker 
lane and 'L' the reaction mix load. ‘V’ refers to a sample from the void peak at ~16 mL 
observed with Gαi/q-RGS2 complex formation. 
 
Isolation of Gαi/q-ΔN-RGS2 complex by gel-filtration was possible with only high 
micromolar concentrations of proteins suggesting that the N-terminus of RGS2 might 
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have a binding surface on Gαq. Our FCPIA assays have also shown that ΔN-RGS2 and -
ΔN-RGS4 binds Gαi/q with a ~15 and 10 fold lower affinity compared to the full-length 
proteins, respectively (Shankaranarayanan, Thal et al. 2008). These results suggested that 
the N-terminus of RGS2/RGS4 might have a binding surface on Gαq. Interestingly, 
studies in Elliot Ross lab predict that the N-terminal helix of Gα subunits is important for 
recognizing RGS proteins (Bohm, Gaudet et al. 1997).  We hypothesized that the 
N-terminal helix of RGS2/RGS4 might contact N-terminus of Gαq. We tested this 
hypothesis by FCPIA assay as described in Appendix III. We did not observe any 
evidence of the N-terminal helix of Gαi1 or Gαq binding RGS proteins. But, the 
N-terminus of RGS2 appears to have a low binding affinity for Gαq.  
 
Results of the gel-filtration analysis of Gα i/q-effector complexes with RGS4/RGS2 
 
Based on our docking model of RGS4 on Gαi/q-GRK2 complex (Fig. 4.2), we expected 
both GRK2 and RGS4 to simultaneously bind Gαi/q on gel-filtration. Surprisingly, the 
Gαi/q·GDP·AlF4--GRK2 complex failed to associate with RGS4 (Fig. 4.6) and similar 
negative results were obtained with RGS2. However, we observed a substoichiometric 
association of RGS2 with the Gαi/q-GRK2-Gβγwt complex (data not shown).  
 
GRK2 binds Gαq in both GTP and GDP·AlF4- bound conformations, while RGS proteins 
preferentially bind the GDP·AlF4- bound form of Gαq (Berman, Kozasa et al. 1996; 
Carman, Parent et al. 1999). This may imply the presence of different conformational 
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states in the Gαq binding pocket and effectors and RGS proteins stabilize discrete states. 
All of our gel-filtration analyses so far were performed with Gαi/q·GDP·AlF4- and hence it 
was important to repeat our gel-filtration analysis with Gαi/q bound to a ligand that is 
more GTP-like (GTPγS and GMPPNP). 
 
 
Figure 4.6. Gel-filtration analysis of GRK2 and RGS4 with Gα i/q·GDP·AlF4-.  RGS4 
does not form a stable complex with AlF4--activated Gαi/q-GRK2 as assessed by size-
exclusion chromatography.  Purified Gαi/q-GRK2 complex was incubated with three 
molar excess of RGS4 in the presence of GDP-AlF4- and then loaded onto tandem 
Superdex 200 gel-filtration columns.  The peak fractions 1 and 2 represent the Gαi/q-
GRK2 complex and RGS4 protein, respectively and were analyzed by SDS-PAGE.  ‘L’ 
denotes the SDS-PAGE analysis of the sample loaded onto the column.  The impurity 
evident below the 37 kDa marker is a substoichiometric amount of Gβγs, which has low 
affinity for GRK2 and co-purified with the Gαi/q-GRK2 complex.  The experiment was 
also performed with a 1.5 and 8 molar excess of RGS4, with the same result. 
 
We loaded Gαi/q with GTPγS using Ric8A as described in methods and tested if 
Gαi/q·GTPγS binds to GRK2 and RGS proteins at the same time. Gαi/q·GTPγS-GRK2 
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complex eluted as a single peak with out any trace of RGS2 association. Similar results 
were obtained with RGS4. Thus even in the GTP bound form, we could not isolate Gαi/q 
in a stable complex of GRK2 and RGS2/RGS4 by size exclusion chromatography. 
 
Figure 4.7. Gel-filtration analysis of GRK2 and RGS2 with Gα i/q·GTPγS. (A) 
Isolation of nucleotide free Gαi/q in complex with Ric8A. Gαi/q·GDP (2 mgs) was 
incubated with Ric8A in the presence of 10 mM EDTA and gel-filtered. (B) RGS2 does 
not form a complex with Gαi/q·GTPγS-GRK2 as assessed by size-exclusion 
chromatography. Nucleotide free Gαi/q-Ric8A complex was incubated with GRK2 and 
RGS2 in the presence of 100 µM GTPγS and 10 mM MgCl2 and gel-filtered. 
Gαi/q·GTPγS-GRK2 complex eluted as a single peak and the excess GRK2, Ric8A and 
RGS2 eluted at lower molecular weight peaks.  
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Since we could not isolate a stable complex of RGS protein and Gαi/q-GRK2-Gβγ, we 
thought that assembling such a complex might be most easily achieved under higher 
protein concentrations. This strategy was used for crystallization and structure 
determination of RGS9-Gαt-PDEγ structure. Thus, we supplemented purified Gαi/q-
GRK2-Gβγ complex with 1.5 molar excess of pure RGS2 or RGS4 and set up 
crystallization trays at ~10 mg/ml protein concentration. We obtained tiny crystals in 
trays set up with the Gαi/q-GRK2-Gβγ complex supplemented with 1.5 molar excess of 
RGS4. The well solution contained 100 mM MES (pH 6.5), 1M NaCl and 
11% PEG 3350. Comparatively better crystals were obtained with detergent additives 
such as CHAPSO, C8H5, CHAPS, Cymal-1, CYPFOS-3 and n-Tridecyl-β-D-maltoside 
when added at its critical micelle concentrations (CMC). Some of these crystals 
diffracted to ~ 20 Å and the crystals will need to be optimized further for a structure 
determination.  
 
In contrast to GRK2, we were able to isolate p63RhoGEF in complex with Gαi/q and 
RGS proteins. We formed RGS4-Gαi/q-p63RhoGEF-RhoA complex as described in the 
methods. All four proteins eluted as a single peak and the peaks corresponding to free 
p63RhoGEF, RGS4 and RhoA were observed at lower molecular weights. Ternary 
complexes of RGS4-Gαi/q-p63RhoGEF could also be purified (data not shown). Thus we 
have direct evidence that RGS4 can interact with Gαi/q-effector (p63RhoGEF) complex. 
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Surprisingly, RGS2 and RGS2ΔN failed to form a ternary complex with 
Gαi/q-p63RhoGEF. 
 
Figure 4.8: Isolation of an RGS4-Gα i/q–p63RhoGEF-RhoA quaternary complex by 
size exclusion chromatography. Peak fractions of the size exclusion run analyzed by 
SDS-PAGE.  Proteins were visualized by Coomassie blue stain.  'M' denotes the protein 
standard marker lane and 'L' the reaction mix load. 
 
Demonstration of RGS-Gαq-effector complex by FCPIA 
 
Gel-filtration chromatography often requires high micromolar concentrations of protein, 
which are not physiological. Therefore, we used FCPIA to test the formation of ternary 
complexes of Gαi/q with effectors and RGS proteins. FCPIA experiments described in 
this chapter were performed with the help of David Thal, graduate student at Tesmer lab. 
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We first measured the direct association of Alexa Fluor 532 (AF) labeled GRK2 (AF- 
GRK2), AF- p63RhoGEF, AF- RGS2 and AF- RGS4 to biotinylated Gαi/q as described in 
Chapter 3. p63RhoGEF used in these studies spans residues 149 through 502 of the full 
length protein and is the construct used for the crystallization of Gαi/q-p63RhoGEF-RhoA 
complex. AF-GRK2, AF-p63RhoGEF, AF-RGS2 and AF-RGS4 bound to Gαi/q with 
dissociation constants of 3, 80, 3, and 5 nM, respectively. We performed homologous 
competition experiments to determine the equilibrium dissociation constants of GRK2, 
p63RhoGEF, RGS2 and RGS4. In these experiments, increasing concentrations of 
unlabeled protein is added to AF-labeled protein, whose concentration is held constant 
near its measured Kd. Ki values of 3, 50, 6 and 9 nM were measured for GRK2, 
p63RhoGEF, RGS2 and RGS4. We also measured the direct binding affinity of ΔN-
RGS2 and ΔN-RGS4 to biotinylated Gαi/q. Compared to the full-length proteins, deletion 
of the amino-termini of RGS2 and RGS4 reduced its affinity for Gαi/q by ~15 and 10 
fold, respectively. Thus the amino termini of RGS2/RGS4 contribute to the binding 
affinity for Gαi/q. 
 
We next used FCPIA to test if RGS proteins modulate the formation of Gαi/q-GRK2 or 
Gαi/q-p63RhoGEF complex (Shankaranarayanan, Thal et al. 2008). Both RGS2 and 
RGS4 compete with AF- GRK2 and AF-p63RhoGEF binding to Gαi/q in the FCPIA 
assay. However, GRK2 was not as effective to inhibit Gαi/q binding to RGS2 or RGS4. 
Also, p63RhoGEF could not efficiently compete with AF-RGS2 or AF-RGS4 binding to 
Gαi/q. The inactive point mutants RGS2 (N149D) and RGS4 (N128G) could not compete 
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AF- GRK2 (or AF-p63RhoGEF) binding to Gαi/q, suggesting that the RGS domains of 
these proteins interact with Gαq in a similar way as observed in Gαi1-RGS4 crystal 
structure (Tesmer, Berman et al. 1997). Taken together, these competition data suggests 
that RGS2 and RGS4 function as negative allosteric modulators of AF-GRK2-Gαi/q or 
AF-p63RhoGEF-Gαi/q complex formation.  
 
In order to directly observe the formation of ternary RGS-Gαi/q-GRK2/p63RhoGEF 
complex using FCPIA, we incubated biotinylated RGS2/RGS4 bound to 
streptavidin-coated beads with a fixed concentration of unlabeled Gαi/q in the presence of 
increasing concentrations of AF-GRK2 or AF-p63RhoGEF. In this experiment, bead-
bound fluorescence would be observed only when a ternary 
RGS-Gαi/q-GRK2/p63RhoGEF complex is formed. In the presence of Gαi/q·AlF4-, RGS4 
exhibited saturable binding to AF-GRK2 with a measured Kd ~ 4 fold higher than the 
intrinsic binding affinity of AF-RGS4 to Gαi/q. However, RGS2 showed little or no 
ability to form a ternary complex suggesting that RGS2 might exhibit a stronger negative 
allosteric effects than RGS4. Analogous experiments with p63RhoGEF gave similar 
results, but the results were less reproducible due to poor labeling/signal that we routinely 
observe for AF-p63RhoGEF. However, we were able to demonstrate the formation of 
RGS4-Gαi/q-p63RhoGEF directly by size exclusion chromatography (Fig. 4.8). 
 
In spite of the high sequence and structural similarity between RGS2 and RGS4, we have 
thus far been able to isolate a ternary complex with RGS4, but not with RGS2. In the 
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absence of Gα-RGS2 structure, it remained possible that RGS2 binding site on Gαq 
overlaps with the effector-binding site of Gαq. The N149D mutant of RGS2 is analogous 
to the N128G mutant of RGS4 that alters a key residue in the Gα-RGS interface. Since 
the N149D mutant of RGS2 did not compete with GRK2 binding to Gαi/q, the RGS box 
of RGS2 and RGS4 are expected to bind Gαi/q as observed in Gαi1-RGS4 crystal 
structure. To eliminate the possibility that the N-terminus of RGS2, but not RGS4, docks 
on the effector binding site of Gαq, we tested RGS2 binding to the effector site mutants 
of Gαq in a pull-down assay.  
 
Figure 4.9: RGS2 pull down of Gαq effector site mutants. Wild type or mutant Gαq 
expressed in HEK293 cells were tested for its ability to bind RGS2 in the 
presence/absence of GDP·AlF4- and bound Gαq was detected by western analysis. Similar 
results were obtained for RGS4. Equal expression of WT Gαq and mutants were 
confirmed prior to pull-down experiment by western analysis.  
 
All the effector site mutants of Gαq appear to bind both RGS2 and RGS4 equally well 
(Fig. 4.9). Thus we do not have any evidence that RGS2 binds Gαq in a fundamentally 
different manner than how RGS4 was modeled (Fig 4.2). It appears that the amino-
termini of RGS2 and RGS4 contribute to Gαi/q binding affinity through non-specific 
interactions. 
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To distinguish the effects of RGS2 and RGS4 on Gαq-effector complexes as direct 
competition or allosteric modulation, we used FCPIA to measure the binding of a fixed 
amount of AF-GRK2 to biotinylated Gαi/q in the presence of increasing amounts of 
RGS2 or RGS4 (Shankaranarayanan, Thal et al. 2008). As expected for a negative 
allosteric model, increasing amounts of RGS2 or RGS4 increases the apparent Kd for AF-
GRK2 binding to Gαi/q and saturates at higher concentrations of RGS proteins. The 
cooperativity factor (α) for RGS2 was calculated as 22 ± 2.3 and that of RGS4 to be 5 ± 
0.5. Thus RGS2 and RGS4 lower the binding affinity of GRK2 to Gαi/q by ~ 22 fold and 
~ 5 fold, respectively. To further confirm the negative allostery of RGS2/RGS4 on 
Gαi/q-GRK2 binding, we measured the dissociation rate of AF-GRK2 from Gαi/q in the 
presence of saturating amounts of unlabeled GRK2, GRK2+RGS2 or GRK2+RGS4. If 
RGS2 and RGS4 are allosteric ligands, they should change the dissociation rate of 
orthosteric ligand (unlabeled GRK2). RGS2 increased the dissociation rate of GRK2 
from 0.05 min-1 to 0.17 min-1 or 3.3 fold. RGS4 had only a slight effect on the 
dissociation rate of GRK2 (0.065 min-1 Vs 0.05 min-1). A 3.3 fold increase in the 
dissociation rate of GRK2 in the presence of RGS2 does not account for a ~22 fold 
decrease in the binding affinity of GRK2 to Gαi/q in the presence of RGS2. Thus RGS2 is 
expected to increase the association rate of GRK2 to Gαi/q by ~ 6 fold. Thus our data 
suggests that RGS2 and RGS4 are strong and weak allosteric modulators, respectively, of 
the effector-binding site of Gαq.  
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Demonstration of RGS-Gαq-effector complex by functional assays 
 
The allostery between RGS and effector binding sites of Gαq could potentially affect the 
activity of these proteins as observed for Gαt, PDEγ and RGS9. We first tested if GRK2 
and p63RhoGEF modulate the GAP activity of RGS2 and RGS4 on Gαq. Gαq binds GTP 
too slowly to allow preparation of the Gαq·GTP substrate needed for a straightforward 
GAP assay. GTPase deficient Gαi/qR183C mutant is routinely used to demonstrate GAP 
activity in single turnover assays. Arg183 is at the beginning of switch I in Gαq and 
stabilizes the negative charge on the γ-phosphate of GTP during the transition state of 
GTP hydrolysis. .  The residue does not interact with effectors or with RGS proteins in 
crystal structures.  The Gαq R183C mutant hydrolyses GTP slowly, facilitating 
measurement of GAP activity, but still activates its effectors PLCβ and p63RhoGEF, 
binds GRK2, and responds to the GAP activity of RGS proteins (Conklin, Chabre et al. 
1992; Carman, Parent et al. 1999; Lutz, Shankaranarayanan et al. 2007).   
 
We first measured the GAP activity of 200 nM RGS2, RGS4 and ΔN-RGS2 (Fig. 4.10a).  
Under the experimental conditions described above, Gαi/qR183C hydrolyzed GTP at a 
basal rate of 0.004 ± 0.001 min-1, consistent with earlier published results (Chidiac and 
Ross 1999). Addition of 200 nM RGS2 stimulated this rate 30-fold, while 200 nM RGS4 
produced a 11-fold increase.  Despite the lower apparent affinity of ΔN-RGS2 protein for 
b-Gαi/q·AlF4-, this protein had higher GAP activity than wild-type RGS2 (80-fold over 
basal). To avoid saturating the GAP activity, we measured GTP hydrolysis on 
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Gαi/qR183C using RGS proteins at 100 nM, at which the apparent rate constants were 
0.06 ± 0.02, 0.012 ± 0.001 and 0.16 ± 0.02 min-1 for RGS2, RGS4, and ΔN-RGS2, 
respectively.  This also enabled us to measure the RGS-stimulated release of 32P over a 
15 min time course with approximately linear kinetics (Fig 4.11).   
 
In the absence of RGS proteins, neither GRK2 nor p63RhoGEF significantly stimulated 
GTP hydrolysis on Gαi/qR183C (Fig. 4.10 & 4.11). However, GRK2 could 
synergistically activate the GAP activity of RGS4 to a maximum of ~ 4 fold over RGS4 
alone. The 4 fold enhancement we measured for RGS4 and GRK2 is similar to the 
cooperative interaction of RGS9 and PDEγ for Gαt. p63RhoGEF also activated the GAP 
activity of RGS4 to a maximum of ~ 1.4 fold at 100 nM p63RhoGEF. Point mutants of 
GRK2 (D110A) and p63RhoGEF (F471E) that are deficient in binding to Gαq did not 
enhance the GAP activity of RGS4 indicating that the enhanced rates we observe in the 
assay are specific (Fig 4.12).  In contrast to RGS4, RGS2-mediated GAP activity was not 
significantly affected by GRK2 or p63RhoGEF (Fig 4.10). 
 
 
 
 
 
 
 
 148 
Figure 4.10. Modulation of GAP activity by GRK2 and p63RhoGEF.  (A) 
Comparison of the GAP activity of 200 nM of each RGS protein on Gαi/qR183C.  In this 
experiment, data were fit to a one phase exponential to give rate constants of 0.005 
(basal), 0.12 (RGS2), 0.044 (RGS4), and 0.31 (ΔN-RGS2) min-1.  (B) The effect of 
GRK2 on the GTPase activity of Gαi/qR183C·GTP in the presence and absence of 100 
nM RGS protein.  The amount of 32P released at 2, 5, 10, and 15 minutes were quantified 
and fit to lines.  The slopes were then normalized either with respect to basal activity 
(GRK2 alone curves) or with respect to the 100 nM RGS slope (GRK2 + RGS protein 
curves).  The 20 nM GRK2 time point in the RGS4 curve and the 20 and 200 nM time 
points in the RGS2 curve are from a single experiment.  The remaining time points 
represent the means ± SD of 2-7 experiments.  (C) The effect of p63RhoGEF on the 
GTPase activity of Gαi/qR183C·GTP in the presence or absence of RGS proteins.  The 
200 nM time point in the RGS4 curve and the 50 and 200 nM time points in the RGS2 
curve are from a single experiment.  The remaining time points represent the means ± SD 
of 3-6 experiments. 
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Figure 4.11: Typical results of a GAP assay (A-D) Time courses (2, 5, 10 and 15 min) 
of GTP hydrolysis were monitored in a GTPase Assay as described above.  The data was 
fit to a straight line with shared intercepts. Gαi/q R183C GTPase activity measured in the 
absence of any additional proteins is referred as basal. (A) Gαi/q R183C GTPase activity 
measured in the presence of 100, 400 or 800 nM GRK2. (B) Gαi/q R183C GTPase 
activity measured in the presence of 100, 400 or 800 nM p63RhoGEF. (C) Synergistic 
enhancement of RGS4 GAP activity by GRK2. Gαi/q R183C GTPase activity was 
measured in the presence of 100 nM RGS4 alone or 100 nM RGS4 in the presence of 2, 
20 or 50 nM GRK2. (D) Inhibition of RGS2 GAP activity by at high concentrations of 
GRK2. Gαi/q R183C GTPase activity was measured in the presence of 100 nM RGS2 or 
100 nM RGS2 alone in the presence of 100, 400 or 800 nM GRK2.  
 
 
At concentrations higher than 200 nM GRK2 or p63RhoGEF, the GAP activity of RGS2 
and RGS4 decrease. 400 nM GRK2-D110A or p63RhoGEF F471E did not have this 
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effect, showing that the decrease in the GAP activity of RGS2/RGS4 requires the 
formation of Gαi/q complex with GRK2 or p63RhoGEF (Fig. 4.12). The decrease in the 
GAP activity of RGS protein is not dependent on the amino terminus of RGS protein, 
since both ΔN-RGS2 and full-length RGS2 showed decreased GAP activity at higher 
concentrations of GRK2 or p63RhoGEF. Since GAP assay is not an equilibrium assay, its 
possible that the association rate of RGS protein on Gαi/q is slowed down at high 
concentrations of GRK2 or p63RhoGEF. 
 
Figure 4.12. Specificity of allostery exhibited GRK2 and p63RhoGEF on GAP 
activity of RGS2/RGS4. (A) The enhancement of RGS4-stimulated GTP hydrolysis by 
GRK2 and p63RhoGEF is specific. The GRK2-D110A and p63RhoGEF-F471E Gaq-
binding deficient mutants, used at the same concentrations as their wild-type equivalents, 
were deficient in stimulating GTP hydrolysis.  Data points represent the mean fold over 
RGS ± S.D (n=3).  Data were analyzed with a Tukey’s post-test.  Three asterisks 
indicates a significant difference between the indicated columns at the p<0.001 level. (B) 
The gradual decrease in RGS2-mediated GTP hydrolysis at higher concentrations of 
GRK2 and p63RhoGEF is specific.  The GRK2-D110A and p63RhoGEF-F471E Gαq-
binding deficient mutants could not inhibit ΔN-RGS2-mediated GTP hydrolysis to the 
same extent as their wild-type equivalents.  Data points represent the mean fold over 
RGS ± S.D (n=3).  Three asterisks indicates a significant difference between the 
indicated columns at the ANOVA p<0.001 level. 
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We next tested if the allosteric modulation exhibited between RGS and effector-binding 
site of Gαq could affect the effector activity in a GAP independent manner. Since there is 
no Gαq -stimulated functional activity of GRK2 that can be measured in vitro (Carman, 
Parent et al. 1999), we tested if Gαi/q·AlF4- stimulated p63RhoGEF activation of RhoA is 
modulated by RGS protein in a GAP independent manner. We monitored the GEF 
activity of p63RhoGEF on RhoA by the fluorescence polarization assay as described in 
chapter 3. Both RGS4 and RGS2 can dramatically reduce the activity of Gαi/q-
p63RhoGEF (Fig. 4.13).  The inhibition was specific, because 2 µM RGS2-N149D and 
2 µM RGS4-N128G had no affect on the rate of Gαi/q-stimulated GEF activity on RhoA.  
Experiments in which the addition of RGS protein was delayed by one or two hours did 
not generate differences in inhibition (data not shown), suggesting that the observed loss 
of exchange activity is not a kinetic artifact due to changes in association or dissociation 
kinetics.  Thus, it appears that RGS proteins are able to modulate the activity of 
p63RhoGEF through both an allosteric and a GAP mechanism.  
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Figure 4.13. Inhibition of Gα i/q-stimulated p63RhoGEF activity by RGS2 and 
RGS4.  Nucleotide exchange on RhoA was monitored by the increase in fluorescence 
millipolarization (mP) of BODIPY FL GTPγS upon binding RhoA.  The resulting data 
were fit as one phase exponentials and are expressed here as the average fold over basal 
exchange ± SD from three independent experiments, each measured in triplicate.  Two 
asterisks indicate an ANOVA p<0.01 and three asterisks an ANOVA p<0.001 between 
the indicated column and the nucleotide exchange mediated by the “No RGS” column. 
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Implications of a RGS-Gαq-effector complex  
 
Positive allostery between Gαt, RGS9 and PDEγ was observed previously and shown to 
be important for the physiological rates of visual signal transduction. Negative allostery 
of Gαt-PDEγ interaction was also observed for RGS4 and RGS16 (Nekrasova, Berman et 
al. 1997; McEntaffer, Natochin et al. 1999). In our study, we have shown that Gαq-
effector interaction is also negatively allosterically modulated by RGS2 and RGS4. The 
GAP activity of RGS4 on Gαq is allosterically stimulated by GRK2 and p63RhoGEF, 
while there was no effect on RGS2 GAP activity. RGS2 and RGS4 allosterically inhibit 
the Gαi/q stimulated nucleotide exchange activity of p63RhoGEF. Since Gαt is a typical 
member of Gαi subfamily and Gαq is a typical member of the Gαq/11 subfamily, it 
appears that the allosteric modulation between the RGS and effector binding sites is 
possible for all Gα subunits that bind RGS proteins.  
 
 
 
GRK2 and p63RhoGEF not only bind to the same site on Gαq, but are also modulated by 
RGS proteins in a similar fashion. This supports the hypothesis that GRK2 is an effector 
of Gαq whose function can be regulated by RGS proteins in vivo. Since the kinase 
activity of GRK2 is not affected by Gαq interaction in vitro (Carman, Parent et al. 1999), 
the role of Gαq in GRK2 signaling might be translocation of GRK2 to its targets at the 
cell membrane similar to the role of Gβγ in GRK2 function. GRK2 stimulated RGS GAP 
activity on Gαq would rapidly turn Gαq to inactive GDP-bound state, which would 
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sequester Gβγ and terminate signaling. Thus its possible that RGS proteins can indirectly 
regulate the phosphorylation of activated GPCR by GRK2 and that the upregulation of 
RGS proteins in cells also lead to loss of GRK2-mediated phosphorylation of 
Gαq-coupled GPCRs, thereby regulating the receptor number at the cell membrane. 
 
In summary, our data supports the idea that the ternary complexes of Gαq, effector and 
RGS proteins form during signal transduction. The orientation of Gαi/q in both GRK2 and 
p63RhoGEF bound structures is similar with respect to the membrane and this orientation 
may be conserved to promote the simultaneous interaction of RGS proteins and effectors 
on Gαq. Perhaps, the activated GPCR is also a part of such higher order complex that 
assemble in response to receptor activation. 
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Chapter 5 
 
 
Conclusion and Future Studies 
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Gαq-coupled receptors have diverse physiological roles in cardiac, brain, lung and 
platelet function. Historically, the cellular responses mediated by Gαq family members 
have been attributed only to the inositol lipid signaling through PLCβ. However, research 
in recent years has identified various downstream binding partners for Gαq that include 
novel effectors, regulators and scaffolding proteins (Hubbard and Hepler 2006).  
Investigation about the cellular responses downstream of these signaling partners and 
whether Gαq family members (Gαq, Gα11, Gα14, Gα15/16) exhibit functional diversity in 
these interactions is currently an active area of research. Structural and biochemical 
studies of Gαq and its signaling complexes have long been hampered by the inability to 
produce sufficient quantities of pure Gαq in both prokaryotic and eukaryotic expression 
systems. We have overcome this difficulty by producing a chimeric Gαq (Gαi/q) that has 
enabled us to determine the crystal structure of two Gαq signaling complexes, 
Gαi/q-GRK2-Gβγ and Gαi/q-p63RhoGEF-RhoA (Tesmer, Kawano et al. 2005; Lutz, 
Shankaranarayanan et al. 2007) and also to perform biophysical and kinetic studies of 
their regulation by RGS proteins (Shankaranarayanan, Thal et al. 2008). The two 
structures represent the only two Gαq structures to date and they provide molecular 
details of activated Gαq signaling complexes that assemble upon activation of a 
Gq-coupled receptor. The structures have enabled us to develop general paradigms for 
Gαq signal transduction, which has opened several avenues for exciting research in the 
future.  
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Functional significance of Gαq-GRK2 interaction  
  
GRK2 has long been known as a negative regulator of Gαq signaling, since it not 
only phosphorylates the activated receptor and initiates its desensitization, but also 
sequesters activated Gαi/q and Gβγ from their effectors. However, simultaneous 
association with Gα and Gβγ is a feature shared by GRK2 and other classic effectors 
such as adenylyl cyclase and PLCβ. The Gαi/q-GRK2-Gβγ structure shows that the RH 
domain of GRK2 binds Gαq as an effector. The Gαq effector-site interaction and the 
orientation of Gαq with respect to the membrane plane are strikingly similar in both the 
GRK2 and p63RhoGEF bound structures (Fig. 2.10, 3.14 & 3.15). Also, Gαq interaction 
with GRK2 and p63RhoGEF is modulated by RGS2 and RGS4 in a similar fashion, 
further driving the question if GRK2 can initiate its own signaling cascade as a Gαq 
effector. Although one obvious pathway is the phosphorylation of the GPCR itself, 
GRK2 is shown to phosphorylate IRS-1, p38 MAP kinase and ezrin in response to 
activation of Gq-coupled receptor (Cant and Pitcher 2005; Usui, Imamura et al. 2005; 
Peregrin, Jurado-Pueyo et al. 2006). Because the catalytic activity of GRK2 is not 
affected by Gαq interaction (Carman, Parent et al. 1999), the role of Gαq in the regulation 
of GRK2 signaling might just be the translocation of GRK2 to its phosphorylation targets 
at the cell membrane. Future studies should focus on understanding if these GRK2-
mediated phosphorylation events are dependent on the direct association of activated Gαq 
with GRK2 and what cellular roles they play. 
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The knockouts of Gαq/11 subunits or GRK2 are embryonic lethal in mice due to cardiac 
myoplasia suggesting that Gαq-GRK2 interaction may be an important signaling event 
essential for normal cardiac development and function. The invertebrate ortholog of 
GRK2 plays the role of rhodopsin kinase in the invertebrate phototransduction cascade, a 
pathway transduced by Gαq-mediated inositol lipid signaling (Lee, Xu et al. 2004). Even 
though a direct interaction between invertebrate rhodopsin kinase and Gαq is not 
reported, its intriguing from an evolutionary perspective that these proteins have been 
working together in the same cascade over millions of years. It is therefore imperative to 
investigate the functional importance of Gαq-GRK2 interaction in cell-based/whole 
animal studies.  
 
Investigation of the inactive conformation of p63RhoGEF 
 
The structure of Gαi/q-p63RhoGEF-RhoA complex provides a snapshot of three 
nodes of signal transduction, captured in the action of relaying signal from heterotrimeric 
G proteins to small G proteins. The structure shows molecular details of how Gαq 
stabilizes both the DH and PH domains of p63RhoGEF in an active conformation for the 
catalytic DH domain to engage RhoA. We have also shown that Gαq activates 
p63RhoGEF-related family members, Trio and Duet, perhaps with a similar mechanism. 
Although, we have identified residues in the C-terminus of their DH domains that 
contribute to its low nucleotide exchange rate in the inactive state (Fig. 3.22), we still 
lack molecular insight into the inactive auto-inhibited state of p63RhoGEF. In order to 
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understand the inactive conformation of p63RhoGEF, future studies should focus on 
crystallizing p63RhoGEF or its family members Trio and Duet in isolation. 
 
Recent studies report a novel interaction between p63RhoGEF with mixed lineage 
kinase 3 (MLK3), which is a mitogen activated protein kinase kinase kinase (MAP3K) 
(Swenson-Fields, Sandquist et al. 2008). MLK3 was originally known to bind Rac1 and 
cdc42, but not RhoA. The recent study shows that MLK3 negatively regulates 
Gαq-mediated signaling to RhoA by directly binding and sequestering p63RhoGEF. It 
would be interesting to investigate if MLK3 also sequesters p63RhoGEF family 
members, Trio and Duet. Crystallographic analyses of p63RhoGEF in complex with 
MLK3 might enable us to visualize an altered, perhaps inactive conformation of 
p63RhoGEF.  
 
Assembly of high order protein complexes at Gq-coupled receptors 
 
The Gαi/q-GRK2-Gβγ structure strongly predicts that Gαq in its activated state 
undergoes a drastic reorientation from its position in the inactive Gαβγ conformation and 
that Gαq and Gβγ subunits completely dissociate from each other upon effector coupling 
(Fig. 2.10). This orientation of activated Gαq is also similar in the 
Gαi/q-p63RhoGEF-RhoA structure suggesting that this reorientation might be a 
conserved feature of Gαq family members upon stimulation by an agonist-activated 
GPCR. Such molecular dynamics needs to be confirmed by site-specific labeling of Gαq 
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protein and monitoring its orientation in lipid bilayers upon activation/effector-
interaction.  
 
Furthermore, our crystal structures demonstrate that both GRK2 and p63RhoGEF interact 
with Gαq in a manner that does not appear to occlude the binding of RGS domain of 
RGS2 or RGS4. The positions of the modeled RGS domains on Gαi/q-GRK2-Gβγ and 
Gαi/q-p63RhoGEF-RhoA complex structures are consistent with the predicted orientation 
of these complexes with respect to the membrane plane, in that the membrane interacting 
elements on RGS proteins are juxtaposed with predicted membrane surface (Fig 4.2). 
Thus it appears that this orientation of Gαq is conserved to promote the assembly of high 
order protein complexes at activated Gq-coupled receptors at the cell membrane. 
 
We have shown through kinetic studies that RGS-Gαq-effector ternary complex do form 
and that RGS2/RGS4 modulate Gαq-effector complexes by both allosteric and GAP-
mediated mechanisms. Similar to the RGS9-Gαt-PDEγ mediated visual signaling, we 
propose that the formation of RGS-Gαq-effector complexes is important for physiological 
rates of termination of Gαq signaling. Since Gαt is a representative member of Gαi 
family and Gαq is a representative member of Gαq/11 family, allosteric modulation 
between effectors and RGS proteins appears to be true for all Gα subunits that bind RGS 
proteins. It is intriguing that in spite of the high structural diversity of the effectors, the 
ability to form an RGS-Gα-effector complex is conserved, perhaps to maintain efficient 
signal transduction and high time resolution. Since RGS proteins are also shown to 
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interact with GPCRs, activated receptors might also be a part of this high order complex. 
Crystallographic analyses of such high order protein complexes would enable us to 
understand how these proteins coordinate to enable rapid nucleotide recycling on Gα 
subunit, yet maintain efficient signal transduction to induce physiological changes.  
 
In summary, our structures of Gαq signaling complexes and the related structure-function 
studies provide molecular details of protein-protein interactions that induce profound 
changes at cellular and organism level. Understanding such protein interfaces is a key 
step towards structure-based drug design and molecular therapeutics that can be targeted 
to treat diseases concerned with impaired Gq signaling cascade.  
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Trypsin Protection Assay on Gα subunits 
 
Limited trypsin digestion of activated Gα subunits is a standard test used to study the 
integrity of their protein fold. While Gα·GDP gets completely digested by trypsin 
treatment, Gα subunits get protected from trypsin digestion in the presence of GDP-AlF4- 
or GTPγS (Tesmer, Kawano et al. 2005). Gα·GTPγS and Gα·GDP·AlF4- get cleaved near 
their amino terminus to generate species that is further resistant to proteolysis (Lee, 
Taussig et al. 1992).   
 
Figure A.1 Trypsin protection Assay of Gα i/q.  Gαi/q (100 µg) was incubated with 
0.01%, 0.05% or 0.1% w/w of trypsin in 50 µl of assay buffer (20 mM HEPES pH 8.0, 
100 mM NaCl, 10 mM β-Me, 5 mM MgCl2, 50 µM GDP) in the presence or absence of 
10 mM NaF and 30 µM AlCl3. The assay was performed at room temperature. At the 
specified time points, 10 µl aliquots were added to 3 µl of SDS loading buffer and 
reaction terminated by boiling the sample for 2 min. The samples were analyzed by 
SDS-PAGE and visualized by Coomassie staining.  
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Crystallization trials of RGS4 bound to CCG4986 
 
In 2007, Roman et al identified CCG-4986 (1-methyl N-[(4-chlorophenyl)sulfonyl]-4-
nitrobenzenesulfinimidoate) as an inhibitor of RGS4-Gαo interaction, RGS4 GAP 
activity and RGS4 activity on µ-opioid receptor-mediated signaling (Roman, Talbot et al. 
2007). It was later shown that CCG-4986 is a covalent modifier of Cys132 of RGS4 in 
the Gα interaction face. CCG-4986 binds RGS4 with an apparent Kd of 10 µM.  
 
 
 
 
 
 
In collaboration with the Neubig lab, we tried to crystallize the full-length RGS4 in 
complex with CCG-4986. RGS4 was purified as described before (Tesmer, Berman et al. 
1997) and concentrated to ~200-400 µM. CCG-4986 was dissolved in DMSO to make a 
20 mM stock and added to RGS4 (20 mM HEPES, pH 8.0, 100 mM NaCl) so that the 
final concentration of the inhibitor is ~ 1 – 1.2 mM. RGS4-CCG-4986 was subject to 
crystallization trials, but no crystals were obtained. Presence of reducing agents in the 
protein buffer turned the solution yellow upon addition of the CCG-4986. The yellow 
color is likely due to the covalent interaction between CCG-4986 and the reducing agent.  
 
Cl
S OO
N
S
NO2
O
H3C
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Potential role of the N-terminus of RGS2 in binding Gαq   
 
Full-length RGS2 and RGS4 bind Gαi/q with 15- and 10-fold increased affinity compared 
to the constructs that lack their amino termini (ΔN-RGS2 and ΔN-RGS4) (Table 4.1). It 
remained possible RGS2 and RGS4 may have a second binding site on Gαq mediated by 
their amino terminus. We cloned the amino termini (residues 1-71) of RGS2 into 
pMALc2H10T vector and purified it as MBP-fusion protein from E.coli 
(MBP-RGS2 (1-71)). We performed a competition assay using FCPIA to see the effect of 
increasing concentrations of MBP-RGS2 (1-71) on the binding of fluorescently labeled 
RGS2 and biotinylated Gαi/q on beads. MBP-RGS2 (1-71) competed with Gαi/q-RGS2 
binding with an EC50 of ~1 µM. Thus, it appears that the N-terminus of RGS2 and RGS4 
have a weak binding affinity for Gαq subunits. Data from the Elliot Ross lab shows that 
the N-terminal truncation of Gαz abolishes its response to the GAP activity of RGS4. If 
the N-terminus of RGS2/RGS4 interacts non-specifically with Gαq, a potential binding 
site could be the N-terminal helix of Gα subunit. We cloned the N-terminal residues of 
Gαq- (1-38) and Gαi1- (1-32) into pMALC2H10T vector and purified it as MBP-tagged 
proteins. We tried to compete biotinylated-Gαq interaction with 5 nM AF 532 labeled 
RGS2, RGS4 or GRK2 in an FCPIA assay with increasing concentrations of unlabeled 
MBP-Gαq- (1-38) or unlabeled MBP-Gαi1- (1-32). These experiments were performed 
with long Gαi/q chimera protein after TEV digestion (Fig. 2.3). In such an assay, neither 
Gαq- (1-38) or Gαi1- (1-32) competed with Gαq interaction with RGS2/RGS4 or GRK2.  
   
 168 
Crystallization trials of Phosducin like protein 1(PhLP1)- Gβγ complex with Gβγ  
 
PhLP1 is an essential chaperone in the folding and assembly of the nascent G protein Gβγ 
subunits. As a collaboration project with Dr. Barry M. Willardson’s lab, we tried to 
crystallize the PhLP1-Gβ1γ2 complex. Our crystallization trials did not yield any crystals. 
 
 
Figure A.3: Formation of PhLP1-Gβ1γ2 complex: Purified PhLP1 (a gift from Barry 
M. Willardson lab) was incubated with a molar excess Gβ1γs for 15 min on ice and 
loaded onto a tandem superdex S200 columns, pre-equilibrated in 100 mM HEPES 
pH 8.0, 150 mM NaCl and 2 mM DTT. The peak fractions were analyzed by 
SDS-PAGE. Fractions containing PhLP1-Gβ1γ2 were pooled, concentrated and set up for 
crystallization trials. 
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